WO2002029006A2 - Procédé pour le mesurage parallèle des variations génétiques - Google Patents

Procédé pour le mesurage parallèle des variations génétiques Download PDF

Info

Publication number
WO2002029006A2
WO2002029006A2 PCT/US2001/042432 US0142432W WO0229006A2 WO 2002029006 A2 WO2002029006 A2 WO 2002029006A2 US 0142432 W US0142432 W US 0142432W WO 0229006 A2 WO0229006 A2 WO 0229006A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
odnp
target nucleic
nucleotide
immobilized
Prior art date
Application number
PCT/US2001/042432
Other languages
English (en)
Other versions
WO2002029006A3 (fr
Inventor
Jeffrey Van Ness
David J. Galas
Lori K. Garrison
Original Assignee
Keck Graduate Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU1183902A priority Critical patent/AU1183902A/xx
Application filed by Keck Graduate Institute filed Critical Keck Graduate Institute
Priority to US10/398,006 priority patent/US20040019005A1/en
Publication of WO2002029006A2 publication Critical patent/WO2002029006A2/fr
Publication of WO2002029006A3 publication Critical patent/WO2002029006A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • This invention relates to the field of molecular biology, more particularly to methods and compositions involving nucleic acids, and still more particularly to methods and compositions for parallel measurement of genetic variations.
  • the chromosomal mapping and nucleic acid sequencing of each of the 80,000 to 100,000 human genes, achieved through the Human Genome Project, provides an opportunity for a comprehensive approach to the identification of nucleotide loci responsible for genetic diseases.
  • Many of the 150-200 common genetic diseases and ⁇ 600-800 of the rarer genetic diseases are associated with one or more defective genes. Of these, more than 200 human diseases are known to be caused by a defect in a single gene, often resulting in a change of a single amino acid residue. (Olsen, "Biotechnology: An Industry Comes of Age” (National Academic Press, 1986)).
  • Mutations occurring in somatic cells may induce disease if the mutations affect genes involved in cellular division control, resulting in, for example, tumor formation.
  • loss-of-function mutations in many genes can give rise to a detectable phenotype in humans.
  • the number of cell generations in the germline, from one gamete to a gamete in an offspring, may be around 20-fold greater in the male germline than in the female.
  • an egg is formed after a second meiotic division and lasts for 40 years. Therefore the incidence of different types of germline mutations and chromosomal aberrations depends on the parent of origin.
  • cytogenetics remains the preferred technique to investigate these important genetic mechanisms.
  • the remaining normal allele may be replaced by a second copy of the mutant allele in one cell per 10 3 -10 .
  • Mechanisms causing this replacement include chromosomal nondisj unction, mitotic recombination, and gene conversion.
  • independent mutations destroying the function of the remaining gene copy are estimated to occur in one cell out of 10 6 .
  • Sensitive mutation detection techniques offer extraordinary possibilities for mutation screening. For example, analyses may be performed even before the implantation of a fertilized egg. (Holding et al., Lancet 3:532 (1989)). Increasingly efficient genetic tests ' may also permit screening for oncogenic mutations in cells exfoliated from the respiratory tract or the bladder in connection with health checkups. (Sidransky et al., Science 252:106, 1991). Alternatively, when an unknown gene causes a genetic disease, methods to monitor DNA sequence variants are useful to study the inheritance of disease through genetic linkage analysis. Notwithstanding these unique applications for the detection of mutations in individual genes, the existing methodology for achieving such applications continues to pose technological and economic challenges. While several different approaches have been pursued, none are sufficiently efficient and cost effective for wide scale application.
  • Non-selective PCR strategies amplify both mutant and wild-type alleles with approximately equal efficiency. Accordingly, low abundance mutant alleles are represented in only a small fraction of the final product. Thus, if the mutant sequence comprises ⁇ 25% of the amplified product, it is unlikely that DNA sequencing approaches will be able to detect its presence.
  • ASOs allele-specific oligonucleotides
  • allele-specific PCR methods can rapidly and preferentially amplify mutant alleles.
  • multiple mismatch primers have been used to detect H-ras mutations at a sensitivity of one mutant in 10 5 wild-type alleles and sensitivity as high as one mutant in 10 wild-type alleles have been reported.
  • Haliassos et al Nucleic Acids Res. 77:8093-8099 (1989) and Chen et al, Anal Biochem 244:191-194 (1997).
  • the discriminating mismatch on the 3' primer end i.e., G:T or C:A mismatch
  • G:T or C:A mismatch will be removed in a small fraction of products by polymerase error during extension from the opposite primer on wild-type DNA. Thereafter, these error products are efficiently amplified and generate false positive signals.
  • nucleotide analogs that are designed to base pair with more than one of the four natural bases are termed "convertides.” Base incorporation opposite different convertides has been tested. (Hoops et al., Nucleic Acids Res. 25:4866-4871 (1997)). For each analog, PCR products were generated using Taq DNA polymerase and primers containing an internal nucleotide analog. The products generated showed a characteristic distribution of the four bases inco ⁇ orated opposite the analogs.
  • the present invention fulfills this and other related needs by providing methods for parallel measurement of genetic variations that, inter alia, display increased speed, convenience and specificity.
  • methods according to the present invention are based on the incorporation of unique restriction endonuclease restriction sites flanking and/or encompassing genetic variation loci. These methods exploit the high degree of specificity afforded by restriction endonucleases and employ readily available detection techniques.
  • the present invention provides various methods, including those summarized below:
  • the present invention provides a method for identifying one or more nucleotide(s) at a defined position in a single-stranded target nucleic acid, comprising
  • step (d) cleaving the fragment with a restriction endonuclease that recognizes the complete IRERS; and (e) characterizing a product of step (d) to thereby determine the identity of the nucleotide to be identified.
  • the defined position is polymorphic.
  • a mutation at the defined position may be associated with a disease.
  • diseases include, but are not limited to, bladder carcinoma, colorectal tumors, sickle-cell anemia, thalassemias, al-antitrypsin deficiency, Lesch-Nyhan syndrome, cystic fibrosis/mucoviscidosis, Duchenne/Becker muscular dystrophy, Alzheimer's disease, X-chromosome-dependent mental deficiency, and Huntington's chorea, phenylketonuria, galactosemia, Wilson's disease, hemochromatosis, severe combined immunodeficiency, alpha- 1-antitrypsin deficiency, albinism, alkaptonuria, lysosomal storage diseases, Ehlers-Danlos syndrome, hemophilia, glucose-6-phosphate dehydrogenase disorder, agammaglobulimenia, diabetes insipidus, Wiskott-
  • the single-stranded target nucleic acid is one strand of a denatured double-stranded nucleic acid, including genomic nucleic acid and cDNA. In some embodiments, the single-stranded target nucleic acid is derived from
  • the target nucleic acid is synthetic nucleic acid.
  • the substrate to which a first ODNP may comprise silicon, glass, paper, ceramic, metal, metalloid, or plastics.
  • a first ODNP may non-covalently immobilized to the substrate.
  • a first ODNP may be covalently immobilized to a substrate at its 5' terminus.
  • a first immobilized ODNP may be synthesized on the substrate using a technique such as photolithography.
  • a first ODNP may be first synthesized and subsequently immobilized onto the substrate.
  • nucleotide sequence of the first ODNP that is complementary to the nucleotide sequence of the target nucleic acid is at least 10, 11,
  • nucleotide sequence complementary to the nucleotide sequence of the complement of the target nucleic acid in the second ODNP is at least 10, 11, 12, 13 or 14 nucleotides in length.
  • step (c) of the method comprises performing a polymerase chain reaction.
  • Step (d) of the method may produce a fragment with a blunt end or a 3' overhang.
  • step (d) produces a fragment with a 5' overhang, using a restriction enzyme such as EcoN I, wherein optionally the nucleotide to be identified or the complement thereof is within the 5' overhang, wherein optionally step (e) further comprises filling a 3' recessed terminus corresponding to the 5' overhang with one or more nucleoside triphosphates, wherein optionally step (e) further comprises washing the substrate before filling the 3' recessed terminus, wherein optionally the nucleoside triphosphate comprises a detectable label, wherein optionally the detectable label is a fluorophore or a radioisotope.
  • step (e) may, or may not, be immobilized to the substrate.
  • step (e) is performed at least partially by the use of a technique selected from the group consisting of mass spectrometry, liquid chromatography, fluorescence polarization, electron ionization, gel electrophoresis, and capillary electrophoresis.
  • the invention provides an immoblilized oligonucleotide primer (ODNP), comprising
  • CRS constant recognition sequence
  • IRERS interrupted restriction endonuclease recognition sequence
  • the oligonucleotide sequence of (a) is at least 12, 14, 16, 18, 20, or 22 nucleotides in length.
  • the immobilized ODNP further comprises one or more nucleotides complementary to the target nucleic acid at a location 3' to the first CRS.
  • the ODNP is 15-80 nucleotides in length.
  • the ODNP may be non-covalently immobilized to the substrate.
  • the ODNP is covalently immobilized to the substrate at its 5' terminus.
  • the complete IRERS is recognizable by EcoN I.
  • the defined position in the target nucleic acid is polymo ⁇ hic.
  • a mutation at the defined position in the target nucleic acid is associated with a disease.
  • the invention provides an immobilized oligonucleotide primer (ODNP) having regions A, B, C, D, E and F, the ODNP being partially complementary to a target nucleic acid as shown below:
  • ODNP immobilized oligonucleotide primer
  • A designates an optional linking element that links the 5' end of the ODNP to a solid support
  • B designates an optional nucleotide sequence
  • C designates a nucleotide sequence that is complementary to a nucleotide sequence of a single-stranded target nucleic acid at a location 3' to a defined position "X" of the target nucleic acid
  • D designates a first constant recognition sequence (CRS) of a first strand of an interrupted restriction endonuclease recognition sequence (IRERS), but not a complete IRERS, the complete IRERS being a double-stranded oligonucleotide having the first strand and a second strand and comprising the first CRS and a second CRS linked by a variable recognition sequence (VRS) having a number n of variable nucleotides;
  • VRS variable recognition sequence
  • F designates an optional gap of nucleotides, where the number of nucleotides within regions E and F is within the range 0 to n-1.
  • region A is selected from a polyether and a polyester.
  • Region A may be cleavable in some embodiments.
  • region B comprises 1 to 50 nucleotides.
  • region C comprises 2- 30 nucleotides.
  • region D comprises 2-6 nucleotides.
  • region D has the sequence 5'-CCT-3'.
  • region E comprises 1-8 nucleotides.
  • region E is complementary to the target nucleic acid.
  • F comprises 1-8 nucleotides.
  • the number of nucleotides with regions B, C, D and E is between 15-80 nucleotides.
  • the immobilization of the ODNP may be non-covalent attachment to the solid support.
  • the immobilization is covalent attachment to the solid support.
  • a composition comprising the immobilized ODNP described above and a target nucleic acid is provided.
  • the nucleotide at the defined position in the target nucleic acid may be a single nucleotide polymo ⁇ hism, polymo ⁇ hic or a mutation associated with a disease.
  • Exemplary diseases include, but are not limited to, bladder carcinoma, colorectal tumors, sickle-cell anemia, thalassemias, al-antitrypsin deficiency, Lesch-Nyhan syndrome, cystic fibrosis/mucoviscidosis, Duchenne/Becker muscular dystrophy, Alzheimer's disease, X- chromosome-dependent mental deficiency, and Huntington's chorea, phenylketonuria, galactosemia, Wilson's disease, hemochromatosis, severe combined immunodeficiency, alpha- 1-antitrypsin deficiency, albinism, alkaptonuria, lysosomal storage diseases, Ehlers- Danlos syndrome, hemophilia, glucose-6-phosphate dehydrogenase disorder, agammaglobulimenia, diabetes insipidus, Wiskott-Aldrich syndrome, Fabry's disease, fragile X-syndrome, familial hypercholesterolemia,
  • a plurality of oligonucleotide primers immobilized to the distinct areas wherein an ODNP in the plurality comprises (i) an oligonucleotide sequence complementary to a nucleotide sequence of a single-stranded target nucleic acid at a location 3' to a defined position at which position a nucleotide is to be identified, the oligonucleotide sequence having 3' and 5' termini, and
  • the ODNPs in any one of the distinct areas of the array are homogeneous, but different from the ODNPs in a second distinct area. In other embodiments, the ODNPs in at least one of the distinct areas are heterogeneous. In some embodiments, the ODNPs in any one of the distinct areas are the same as the ODNPs in a second distinct area. ODNPs of the array may be non-covalently immobilized to the substrate.
  • ODNPs are synthesized on the substrate, for example, using the technology of photolithography. In other embodiments, ODNPs are first synthesized and subsequently immobilized to the substrate.
  • each ODNP is 15-80 nucleotides in length. Preferably, for each
  • the oligonucleotide sequence of (i) is at least 10, 11, 12, 13, or 14 nucleotides in length.
  • at least one of tlie ODNPs further comprises one or more nucleotides complementary to the target nucleic acid at a location 3' to the first CRS.
  • the defined position in the target nucleic acid is polymo ⁇ hic.
  • a mutation at the defined position is associated with a disease.
  • the complete IRERS is recognizable by EcoN I.
  • 1000 to 10 12 ODNP molecules of the first set are immobilized in at least one in the plurality of distinct areas.
  • the substrate of the array may have 2-9, 10-100, 101-400, 401-1000, or more than 1000 distinct areas. It may be made of a material such as silicon, glass, paper, ceramic, metal, metalloid, and plastic. In some embodiments, the surface of the array has raised portions to delineate the distinct areas.
  • the single-stranded target nucleic acid may be one strand of a denatured double-stranded nucleic acid, such as genomic DNA.
  • the target nucleic acids complementary to the ODNP(s) that comprise sequences (i) and (ii) are from one organism.
  • the target nucleic acids complementary to the ODNP(s) that comprise sequences (i) and (ii) are from two or more organisms of one species.
  • the present invention provides a method, comprising (a) providing a first set of oligonucleotide primers (ODNPs) immobilized to a substrate in a plurality of distinct areas wherein each ODNP of the first set comprises
  • the ODNPs of the first set in any one of the distinct areas are homogeneous, but different from the ODNPs in a second distinct area. In other embodiments, the ODNPs of the first set in at least one of the distinct areas are heterogeneous. In some embodiments, the ODNPs of the first set in any one of the distinct areas are the same as the ODNPs in a second distinct area.
  • the ODNPs of the first set may be non-covalently immobilized to the substrate. Alternatively, they may be covalently immobilized to the substrate at their 5' termini.
  • the ODNPs are synthesized on the substrate, for example, using the technology of photolithography. In other embodiments, the ODNPs are first synthesized and subsequently immobilized to the substrate. Optionally, each of the first set of ODNPs is 15-80 nucleotides in length.
  • each of the second set of ODNPs is 15-80 nucleotides in length.
  • the oligonucleotide sequence of (i) is at least 10, 11, 12, 13, or 14 nucleotides in length.
  • the oligonucleotide sequence of (i) is at least 10, 11, 12, 13, or 14 nucleotides in length.
  • at least one of the first set of ODNPs further comprises one or more nucleotides complementary to the target nucleic acid at a location 3' to the first CRS.
  • At least one of the second set of ODNPs further comprises one or more nucleotides complementary to the target nucleic acid at a location 3' to the second CRS.
  • the defined position in the target nucleic acid is polymo ⁇ hic.
  • a mutation at the defined position is associated with a disease.
  • diseases include, but are not limited to, bladder carcinoma, colorectal tumors, sickle- cell anemia, thalassemias, al-antitrypsin deficiency, Lesch-Nyhan syndrome, cystic fibrosis/mucoviscidosis, Duchenne/Becker muscular dystrophy, Alzheimer's disease, X- chromosome-dependent mental deficiency, and Huntington's chorea, phenylketonuria, galactosemia, Wilson's disease, hemochromatosis, severe combined immunodeficiency, alpha- 1-antitrypsin deficiency, albinism, alkaptonuria, lysosomal storage diseases, Ehlers-Danlos syndrome, hemophilia, glucose-6-phosphate dehydrogenase disorder, agammaglobulimenia, diabetes insi
  • 1000 to 10 12 ODNP molecules of the first set are immobilized in at least one in the plurality of distinct areas.
  • the substrate may have 2-9, 10-100, 101-400, 401-1000, or more than
  • the surface of the array has raised portions to delineate the distinct areas.
  • the single-stranded target nucleic acid may be one strand of a denatured double-stranded nucleic acid, such as genomic DNA, cDNA.
  • the target nucleic acid is synthetic nucleic acid.
  • the target nucleic acids complementary to the ODNP(s) of the first set are from one organism.
  • the target nucleic acids complementary to the ODNP(s) of the first set are from two or more organisms of one species.
  • step (c) of the method comprises performing a polymerase chain reaction.
  • Step (d) of the method may produce a fragment with a blunt end or a 3' overhang.
  • step (d) produces a fragment with a 5' overhang, using a restriction enzyme such as EcoN I, wherein optionally the nucleotide to be identified or the complement thereof is within the 5' overhang, wherein optionally step (e) further comprises filling a 3' recessed terminus corresponding to the 5' overhang with one or more nucleoside triphosphates, wherein optionally the 3' recessed terminus is filled in with a restriction enzyme such as EcoN I, wherein optionally the nucleotide to be identified or the complement thereof is within the 5' overhang, wherein optionally step (e) further comprises filling a 3' recessed terminus corresponding to the 5' overhang with one or more nucleoside triphosphates, wherein optionally the 3' recessed terminus is filled in with a
  • step (e) further comprises washing the substrate before filling the 3' recessed terminus, wherein optionally the nucleoside triphosphate comprises a detectable label, wherein optionally the detectable label is a fluorophore or a radioisotope.
  • step (e) may, or may not, be immobilized to the substrate.
  • step (e) is performed at least partially by the use of a technique selected from the group consisting of mass spectrometry, liquid chromatography, fluorescence polarization, electron ionization, gel electrophoresis, and capillary electrophoresis.
  • the invention further provides a method, comprising (a) exposing the array described above to one or more target nucleic acids and a set of ODNPs wherein each ODNP of the set comprises
  • the invention provides a kit for genotyping comprising the array described above.
  • the kit may further comprise a restriction endonuclease that recognizes a complete IRERS and/or a DNA polymerase.
  • Figure 1 is a chromatogram obtained from electrospray-liquid- chromatography/mass spectrometry-time of flight (ES-LC/MS-TOF) analysis of a 1 :10 dilution of a 4-mer ODN (5'-ACGA-3').
  • ES-LC/MS-TOF electrospray-liquid- chromatography/mass spectrometry-time of flight
  • Figure 2 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1 :100 dilution of a 4-mer ODN (5'-ACGA-3').
  • Figure 3 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1:1000 dilution of a 4-mer ODN (5*-ACGA-3').
  • Figures 4A and 4B are chromatograms obtained from (ES-LC/MS-TOF) analysis of a 1:10 dilution of a 6-mer ODN (5'-ACGATG-3').
  • Figure 5 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1:100 dilution of a 6-mer ODN (5'-ACGATG-3').
  • Figure 6 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1:1000 dilution of 6-mer ODN (5*-ACGATG-3').
  • Figures 7A and 7B are chromatograms obtained from (ES-LC MS-TOF) analysis of a 1 : 10 dilution of a 8-mer ODN (5'-ACGATGCA-3 *).
  • Figure 8 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1:100 dilution of a 8-mer ODN (5'-ACGATGCA-3').
  • Figures 9A and 9B are chromatograms obtained from (ES-LC/MS-TOF) analysis of a 1:10 dilution of the 10-mer ODN of SEQ ID NO: 8.
  • Figure 10 is a cliromatogram obtained from (ES-LC/MS-TOF) analysis of a 1:100 dilution of the 10-mer ODN of SEQ ID NO: 8.
  • Figure 11 is a chromatogram obtained from (ES-LC/MS-TOF) analysis of a 1 : 1000 dilution of the 10-mer ODN of SEQ ID NO: 8.
  • Figure 12 is a diagram of major steps in one aspect of the present method for identifying a nucleotide at a defined position in a target nucleic acid using two ODNPs and an exemplary restriction endonuclease recognition sequence for EcoN I.
  • Figure 13 is a high pressure liquid chromatogram (HPLC) of a set of 4,
  • Figures 14A and 14B show HPLC separation of three 8-mers (Figure 14 A) and three 10-mers ( Figure 14B).
  • Figures 15A and 15B show the HPLC separation of one 4-mer, one 6-mer, three 8-mers and three 10-mers ( Figure 15 A) and the elution of two 6-mers ( Figure 15B).
  • Figure 16 is a control HPLC chromatogram.
  • Figure 17 shows HPLC fractionation and detection of short fragments generated by restriction enzyme Fok I double digest.
  • Figure 18 shows changes in fluorescence polarization for DNA samples genotyped with the FP-EcoN I assay.
  • Figure 19 is a schematic diagram of the major components of immobilized ODNPs and a resulting amplicon of the present invention.
  • Figure 20 is a schematic diagram of the major components of an interrupted restriction endonuclease recognition sequence.
  • D]D ...D m is a specific nucleotide sequence consisting of m nuleotides, whereas D' 1 D' ...D' m is the complement sequence of D 1 D 2 ...D m .
  • the double-stranded fragment comprised of D ⁇ D ...D m and
  • D']D' 2 ...D' m forms the first CRS (also referred to as "Region D").
  • N]N 2 ...N flesh is a variable nucleotide sequence consisting of n nucleotides where any one of the nucleotide can contain any of the four bases (a, c, t, or g).
  • N']N' ...N' n is the and forms a VRS in combination of NjN ...N n (also referred to as "Region N”) .
  • Region E of immobilized ODNPs of the present invention constitutes a portion of Region N.
  • S 1 S 2 ...Sj is a specific nucleotide sequence consisting of i nucleotides, whereas S']S' ...S'i is the. complement of SiS ... Sj.
  • the double-stranded fragment comprised of S ⁇ S ... Si and
  • FIG. 21 is a schematic diagram of various types of digestion products.
  • Oligonucleotides (a), (b), (c) and (d) designate the following single-stranded oligonucleotides: (a) the immobilized strand that contains the first ODNP, (b) the complementary strand of oligonucleotide (a), (c) the non-immobilized strand that was a portion of an extension product of the first ODNP, and (d) the complementary strand of oligonucleotide (c).
  • the present invention provides methods, compositions, and kits for determining sequence information at a defined genetic loci in a target nucleic acid and for parallel measurement of genetic variations.
  • the invention provides for the design, preparation and use of oligonucleotide primers (ODNPs) that can be extended in a manner that inco ⁇ orates information about the nucleotide of interest into the extension product.
  • ODNPs oligonucleotide primers
  • the resulting product e.g., amplicon
  • This information is advantageously utilized in a variety of applications, as described herein, such as genetic analysis for hereditary diseases, tumor diagnosis, disease predisposition, forensics or paternity, crop cultivation and animal breeding, expression profiling of cell function and/or disease marker genes, and identification and/or characterization of infectious organisms that cause infectious diseases in plants or animals and/or that are related to food safety.
  • the ODNPs of the present invention each contain part of an interrupted restriction endonuclease recognition sequence (IRERS), defined in detail below.
  • the interrupted segment of the restriction endonuclease recognition site also referred to as “variable recognition sequence (VRS)
  • VRS variable recognition sequence
  • the interrupted segment of the restriction endonuclease recognition site may be one or more nucleotides in length and the sequence is variable (each position can contain any of the four bases (a, c, t, or g)).
  • VRS variable recognition sequence
  • the primers are designed such that the nucleotide of interest in a target nucleic acid is located in the amplicon within the variable segment of the restriction endonuclease recognition site.
  • the amplicon can then be digested to generate small fragments of nucleic acid that can be analyzed to determine the nucleotide of interest with great accuracy and sensitivity.
  • the ODNPs of the present invention are shown schematically in Figure 19.
  • One primer of each ODNP pair is immobilized to a substrate to facilitate characterization of digested products.
  • a diagram of the present invention is shown using the exemplary restriction endonuclease recognition sequence for EcoN I.
  • any interrupted restriction endonuclease recognition sequence may be used (see Table 2).
  • the present invention provides assays for determining the identity of a nucleotide at a predetermined location in a target nucleic acid molecule and for parallel measurement of genetic variations.
  • provided herein are compounds and compositions that are useful in performing such assays.
  • the present invention provides compounds and compositions that, upon suitable characterization, identify the base at a predetermined location in a target nucleic acid or measure genetic variation in parallel. Still further aspects of the present invention are described hereinbelow.
  • nucleic acid when a location in a nucleic acid is "5' to" or “5' of a nucleotide of interest, this means that it is between the nucleotide of interest and the 5' phosphate of that strand of nucleic acid.
  • a refers to one or more of the indicated items unless the context clearly indicates otherwise.
  • a polymerase refers to one or more polymerases.
  • the identity of a nucleotide of interest in a target nucleic acid molecule is determined by combining the target with two primers.
  • the first primer is immobilized to a substrate and hybridizes to and extends from a location 3' of the nucleotide of interest in the target, so as to inco ⁇ orate the complement of the nucleotide of interest in a first extension product.
  • the second primer then hybridizes to and extends based on the first extension product, which is immobilized to the substrate via the first primer, at a location 3' of the complement of the nucleotide of interest, so as to inco ⁇ orate the nucleotide of interest in a second extension product.
  • the second extension product then dissociates from the first extension product and thus from the substrate and re-hybridizes to another first primer molecule that has not extended.
  • the non-extended first primer then extends from a location 3' of the nucleotide of interest in the second extension product, so as to form, in combination with the second extension product, a double-stranded nucleic acid fragment.
  • the first and second primers are designed to inco ⁇ orate a portion of the recognition sequence of a restriction endonuclease (RE) that recognizes a partially variable interrupted nucleotide sequence, i.e., a sequence of the form D-N-S where D and S refer to specific nucleotide sequences essential for RE recognition (also referred to as the first constant recognition sequence (CRS) and the second CRS, respectively), and N is a sequence consisting of n viable nucleotides also required for RE recognition.
  • RE restriction endonuclease
  • the first primer inco ⁇ orates the sequence D
  • the second primer inco ⁇ orates the sequence S
  • they are designed, in view of the target, to product a nucleic acid fragment where constant sequences D and S are separated by variable sequence N, where the nucleotide of interest is within region N.
  • Action of the RE on the nucleic acid fragment provides a small nucleic acid fragment that is amendable to characterization, to thereby reveal the identity of the nucleotide of interest.
  • the use of short nucleic acid (e.g., DNA) fragments is advantageous for numerous readout systems because amplicons produced during, e.g., a PCR amplification reaction, need not be tagged or labeled to facilitate detection.
  • the present invention also provides a method of parallel measurement of genetic variations. Genetic variations at defined positions in target nucleic acids are identified by combining the targets with two sets of ODNPs.
  • the first set of ODNPs are immobilized to a substrate in distinct areas.
  • Each ODNP of the two sets is designed to inco ⁇ orate a portion of an IRERS (i.e., CRS) so that the extension and/or amplification product of an ODNP of the first set and its corresponding ODNP of the second set contains a complete IRERS.
  • CRS an IRERS
  • the extension and/or amplification product from the two ODNPs with the target as a template contains the nucleotide at the defined position.
  • the extension and/or amplification product is then digested with a RE that recognizes the IRERS and the resulting small fragment is characterized.
  • the genetic variation at the defined position is thereby identified. Because ODNPs are immobilized in distinct areas of the substrate, the above methods can be used to determine and/or measure genetic variations in multiple target nucleic acids in parallel.
  • the methods of the present invention have one or more of the following advantages: (1) very little target nucleic acid(s) is required; (2) multiple alleles may be assayed simultaneously in a "containerless" setting (i.e., different alleles need not be contained in distinct containers); (3) the ODNPs need not be labeled or tagged; (4) multiple measurements of genetic variations can be made in parallel; (5) the inco ⁇ oration of nucleotides to be identified into small fragments is carried out with high fidelity; (6) no need exists for a dephosphorylation step after extension reactions as all the uninco ⁇ orated oligonucleotides, dNTPs, etc.
  • Methods, kits and compositions of the present invention typically involve or include a target nucleic acid molecule.
  • the target nucleic acid of the present invention is any nucleic acid molecule about which nculeotide information is desired, and which can serve as a template for a primer extension reaction, i.e., can base pair with a primer.
  • nucleic acid refers generally to any molecule, preferably a polymeric molecule, inco ⁇ orating units of ribonucleic acid or an analog thereof.
  • the template nucleic acid can be either single-stranded or double-stranded.
  • the template nucleic acid is DNA.
  • the template is RNA.
  • Suitable nucleic acid molecules are DNA, including genomic DNA, ribosomal DNA and cDNA.
  • Other suitable nucleic acid molecules are RNA, including mRNA, rRNA and tRNA.
  • the nucleic acid molecule may be naturally occurring, as in genomic DNA, or it may be synthetic, i.e., prepared based up human action, or may be a combination of the two.
  • a naturally occurring nucleic acid is obtained from a biological sample.
  • the biological sample can be any sample that contains biological material (e.g., cells, tissues) from any organisms, including but not limited to, animals, higher plants, fungi, bacteria, and viruses.
  • biological material e.g., cells, tissues
  • One type of preferred biological samples include one or more mammalian tissues, (for example blood, plasma/serum, hair, skin, lymph node, spleen, liver, etc) and/or cells or cell lines.
  • the biological samples may comprise one or more human tissues and/or cells. Mammalian and/or human tissues and/or cells may further comprise one or more tumor tissues and/or cells.
  • viruses such as pathogenic viruses (e.g., hepatitis A, B, or C), he ⁇ es vims (e.g., VZN HSV-1, HAV-6, HSV-II, CMV, and Epstein Barr vims), adenoviras, influenza viras, echoviras, rhinovirus, cornovirus, respiratory syncytical viras, mumps virus, measles virus, rubella viras, parvoviras, poliovirus, rabies virus, and flaviviruses.
  • pathogenic viruses e.g., hepatitis A, B, or C
  • he ⁇ es vims e.g., VZN HSV-1, HAV-6, HSV-II, CMV, and Epstein Barr vims
  • adenoviras e.g., influenza viras, echoviras, rhinovirus, cornovirus, respiratory syncytical viras
  • Other preferred biological samples contain genomic or episomic nucleic acids of pathogenic bacteria, particularly regions conferring drug resistance or useful for phylogenic characterization of the host (e.g., 16S rR ⁇ A).
  • pathogenic bacteria include, but is not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, treptocci, pneumonococci, meningococci, conococci, klebsiella, proteus, serratia, pseudomonas, bacilli, cholera, tetanus, anthrax, plague, and Lymes disease bacteria.
  • the biological sample may contain biological material from a single organism, or a population of (i.e., two or more) organisms of a single species.
  • the biological sample may contain biological material from organisms of two or more species.
  • a synthetic nucleic acid is produced by human intervention.
  • many companies are in the business of making and selling synthetic nucleic acids that may be useful as the template nucleic acid molecule in the present invention. See, e.g., Applied Bio Products Bionexus (www.bionexus.net); Commonwealth Biotechnologies, Inc.
  • the synthetic nucleic acid template may be prepared using an amplification reaction.
  • the amplification reaction may be, for example, the polymerase chain reaction.
  • the synthetic nucleic acid template may be prepared using recombinant D ⁇ A means through production in one or more prokaryotic or eukaryotic organism such as, e.g., E. coli, yeast, Drosophila or mammalian tissue culture cell line.
  • the nucleic acid molecule may, and typically will, contain one or more of the 'natural' nucleotides, i.e., adenine (A), guanine (G), cytosine (C), thymine (T) and, in the case of an RNA, uracil (U).
  • the target nucleic acid may include "unnatural" nucleotides.
  • Unnatural nucleotides are chemical moieties that can be substituted for one or more natural nucleotides in a nucleotide chain without causing the nucleic acid to lose its ability to serve as a template for a primer extension reaction.
  • the substitution may include either sugar and/or phosphate substitutions, in addition to base substitutions.
  • Such moieties are very well known in the art, and are known by a large number of names including, for example, abasic nucleotides, which do not contain a commonly recognized nucleotide base, such as adenine, guanine, cytosine, uracil or thymine (see, e.g., Takeshita et al. "Oligonucleotides containing synthetic abasic sites," J. Biol. Chem. 262:10111-10119 (1987); Iyer et al. "Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents" Nucleic Acids Res.
  • abasic nucleotides which do not contain a commonly recognized nucleotide base, such as adenine, guanine, cytosine, uracil or thymine
  • non-natural nucleotides are set forth in: Jaschke et al., Tetrahedron Tett. 34:301 (1993); Seela and Kaiser, Nucleic Acids Res. 15:3113 (1990) and Nucleic Acids Res. 18:6353 (1990); Usman et al., PCT International Patent Application No. PCT/US 93/00833; Eckstein, PCT International Patent Application No. PCT/EP91/01811; Sproat et al, U.S. Pat. No. 5,334,711, and Buhr and Matteucci, PCT International Publication No. WO 91/06556; Augustyns, K. A. et al., Nucleic Acids Res., 1991, 19, 2587-2593); and U.S. Patent No.s 5,959,099 and 5,840,876.
  • base-pair mismatch refers to all single and multiple nucleotide substitutions that perturb the hydrogen bonding between conventional base pairs, e.g., G:C, A:T, or A:U, by substitution of a nucleotide with a moiety that does not hybridize according to the standard Watson-Crick model to a corresponding nucleotide on the opposite strand of the oligonucleotide duplex.
  • Such base-pair mismatches include, e.g., G:G, G:T, G:A, G:U, C:C, C:A, C:T, C:U, T:T, T:U, U:U and A: A.
  • base-pair mismatches are single or multiple nucleotide deletions or insertions that perturb the normal hydrogen bonding of a perfectly base-paired duplex.
  • base-pair mismatches arise when one or both of the nucleotides in a base pair has undergone a covalent modification (e.g., methylation of a base) that disrupts the normal hydrogen bonding between the bases.
  • Base-pair mismatches also include non-covalent modifications such as, for example, those resulting from inco ⁇ oration of intercalating agents such as ethidium bromide and the like that perturb hydrogen bonding by altering the helicity and/or base stacking of an oligonucleotide duplex.
  • the template in addition to containing nucleic acids or analogs thereof, also contains one or more natural bases of unknown identity.
  • the present invention provides compositions and methods whereby the identity of the unknown nucleotide(s) becomes known.
  • nucleotide loci refers to a specific nucleotide or region encompassing one or more nucleotides having a precise location on a target nucleic acid.
  • the base(s) to be identified in the target nucleic acid may be a mutation.
  • mutation refers to an alteration in a wild-type nucleic acid sequence. Mutations may be in regions encoding proteins (exons) or may be in non-coding regions (introns or 5' and 3' flanking regions) of a target nucleic acid. Exemplary mutations in non-coding regions include regulatory mutations that alter the amount of gene product, localization of protein and/or timing of expression.
  • point mutations refers to mutations in which a wild-type base (i.e., A, C, G, or T) is replaced with one of the other bases at a defined nucleotide locus within a nucleic acid sample.
  • a "frameshift mutation” is caused by a small deletion or insertion that, in turn, causes the reading frame to be shifted and, thus, a novel peptide to be formed.
  • a "regulatory mutation” is a mutation in a region(s) of the gene not coding for protein, e.g., intron, 5'- or 3'-flanking, but affecting correct expression (e.g., amount of product, localization of protein, timing of expression).
  • a "nonsense mutation” is a single nucleotide change resulting in a triplet codon (where mutation occurs) being read as a "STOP" codon causing premature termination of peptide elongation, i. e.
  • a "missense mutation” is a mutation that results in one amino acid being exchanged for a different amino acid. Such a mutation may cause a change in the folding (3 -dimensional structure) of the peptide and/or its proper association of other peptides in a multimeric protein.
  • trinucleotide repeat refers to a class of mutations that overlap with the chromosomal disorders, since large deletions in the "trinucleotide repeat" can be seen using cytological methods.
  • a trinucleotide repeat is a 3-base-pair sequence of nucleic acid (typically DNA) in or around the gene which is reiterated tandemly (one directly adjacent to the next) multiple times.
  • the mutation is observed when abnormal expansion of the repeat at variable levels results in the abnormal phenotype.
  • the severity of the disorder can sometimes be correlated with the number of repeats in the expanded region, e.g., fragile X mental retardation syndrome, Huntington Disease, and myotonic dystrophy.
  • the nucleotide of interest i.e., the nucleotide to be identified, may be a "single-nucleotide polymo ⁇ hism" (SNP), which refers to any nucleotide sequence variation, preferably one that is common in a population of organisms and is inherited in a Medelian fashion.
  • SNP single-nucleotide polymo ⁇ hism
  • the SNP is either of two possible nucleotides, and there is no possibility of finding a third or fourth nucleotide identity at an SNP site.
  • a defined nucleotide locus within the target nucleic acid that comprises a nucleotide to be identified may contain a point mutation, single nucleotide polymo ⁇ hism, deletion and/or insertion mutation.
  • the target nucleic acid may also be a complement of such a mutated allele.
  • polymo ⁇ hism or “genetic variation,” as used herein, refers to the occurrence of two or more genetically determined alternative sequences or alleles in a small region (i.e., one to several (e.g., 2, 3, 4, 5, 6, 7, or 8) nucleotides in length) in a population.
  • the allelic form occurring most frequently in a selected population is referred to as the wild type form.
  • Other allelic forms are designated as variant forms. Diploid organisms may be homozygous or heterozygous for allelic forms.
  • the genetic variation may be associated with or cause diseases or disorders.
  • the term "associated with,” as used herein, refers to the correlation between the occurrence of the genetic variation and the presence of a disease or a disorder.
  • diseases include, but are not limited to, bladder carcinoma, colorectal tumors, sickle- cell anemia, thalassemias, al-antitrypsin deficiency, Lesch-Nyhan syndrome, cystic fibrosis/mucoviscidosis, Duchenne/Becker muscular dystrophy, Alzheimer's disease, X- chromosome-dependent mental deficiency, and Huntington's chorea, phenylketonuria, galactosemia, Wilson's disease, hemochromatosis, severe combined immunodeficiency, alpha- 1-antitrypsin deficiency, albinism, alkaptonuria, lysosomal storage diseases, Ehlers-Danlos syndrome, hemophilia, glucose-6-phosphate dehydrogenase disorder
  • Target nucleic acids may be amplified before being combined with ODNPs as described below. Any known methods for amplifying nucleic acids may be used. Exemplary methods, such as the use of Qbeta Replicase, Strand Displacement
  • Amplification, transcription-mediated amplification, RACE, and one-sided PCR are described in detail below.
  • ODNPs Oligonucleotide Primers
  • Methods, kits and compositions of the present invention typically involve or include one or more ODNPs which generally contain one or more partial IRERS s and regions of complementarity with target nucleic acids.
  • the target nucleic acid is described as a single-stranded nucleic acid below.
  • the ODNP(s) of the present invention wherein the target nucleic acid is double-stranded.
  • a double-stranded nucleic acid may be first denatured to form two single-stranded nucleic acids before being mixed with ODNPs.
  • oligonucleotide refers to a nucleic acid fragment (typically DNA or RNA) obtained synthetically as by a conventional automated nucleic acid (e.g., DNA) synthesizer. Oligonucleotide is used synonymously with the term polynucleotide.
  • oligonucleotide primer refers to any polymer having two or more nucleotides used in a hybridization, extension, and/or amplification reaction.
  • the ODNP may be comprised of deoxyribonucleotides, ribonucleotides, or an analog of either.
  • ODNPs are generally between 8 and 200 bases in length. More preferred are ODNPs of between 12 and 50 bases in length and still more preferred are ODNPs of between 18 and 32 bases in length.
  • the present invention provides an immobilized ODNP useful for producing a portion of a target nucleic acid containing a nucleotide to be identified at a defined position in combination of a second ODNP.
  • the immobilized ODNP (“the first ODNP” or “the forward primer”) comprises a nucleic acid sequence complementary to a nucleotide sequence of a target nucleic acid at a location 3' to the defined position ("the first region of the target nucleic acid”)
  • the second primer (“the reverse primer”) comprises a nucleic acid sequence complementary to a nucleotide sequence of the complement of the target nucleic acid, also at a location 3' to the defined position ("the first region of the complement").
  • each ODNP contains at least 5, preferably at least 7, more preferably at least 9, most preferably at least 11 nucleotides that are complementary to the target nucleic acid or the complement thereof.
  • both ODNPs hybridize to a target nucleic acid or the complement thereof at a location 3' to the defined position, the resulting extension and/or amplification products from the two ODNPs contains the nucleotide to be identified at the defined position.
  • the first primer and the second primer each further comprises a partial IRERS, but not a complete IRERS, at a location 3' to, or preferably at the 3' terminus of, its nucleic acid sequence described above (i.e., the sequence complementary to the target nucleic acid or the complement thereof).
  • a complete IRERS is a double-stranded oligonucleotide sequence comprising a first CRS and a second CRS linked with a NRS ( Figure 20).
  • the first OD ⁇ P and the second OD ⁇ P comprise the first CRS of the first strand of the IRERS and the second CRS of the second strand of the IRERS, respectively.
  • the first OD ⁇ P and the second OD ⁇ P are so spaced that (1) the extension and/or amplification product with the OD ⁇ P pair as primers and the target nucleic acid as a template contains a complete IRERS and (2) the nucleic acid to be identified is within the VRS.
  • the number of nucleotides between the first and the second CRS is the exact number of nucleotides in the VRS so that the extension and/or amplification product from both OD ⁇ Ps can be digested by a RE that recognizes the complete IRERS.
  • the partial IRERS in each OD ⁇ P may or may not be complementary to the target nucleic acid.
  • the first primer and/or the second primer further contains one or more nucleotides that is complementary to the target nucleic acid or the complement thereof ("the second region of the target nucleic acid” and “the second region of the complement,” respectively) at a location 3' to, or preferably the 3' terminus of, the CRS.
  • Such nucleotides are a portion of the VRS ( Figure 19).
  • the number of the nucleotides between first and second regions of the target nucleic acid or the complement thereof may be larger or smaller, but preferably equal to, the number of nucleotides of ODNPs between their two regions that complementary to the target nucleic acids or the complement thereof.
  • the immobilized ODNP may comprise additional sequences ( Figure 19).
  • regions A, B, C, D, E and F designate the following elements or sequences: region A — an optional linking element that links the 5' terminus of the ODNP to a substrate; region B — an optional nucleotide sequence; region C — a nucleotide sequence complementary to a nucleotide sequence of a single- stranded target nucleic acid at a location 3' to a defined position "X" of the target; region D — a first CRS of a first strand of a complete IRERS; region E — an optional nucleotide sequence; and region F — an optional gap of nucleotides.
  • region A an optional linking element that links the 5' terminus of the ODNP to a substrate
  • region B an optional nucleotide sequence
  • region C a nucleotide sequence complementary to a nucleotide sequence of a single- stranded target nucleic acid at a location 3' to a defined position "X" of the target
  • the nucleotide sequence of region E is complementary to a nucleotide sequence of the target near the nucleotide sequence of the target that is complementary to region C.
  • the overall complementary between the ODNP and the target (via region C and region E, if applicable, of the ODNP) must be sufficient for the ODNP to selectively hybridize with the target so that the ODNP is able to function as a primer for extension and/or amplification using the target as a template.
  • the number of nucleotides within regions E and F is witliin the range 0 to n-1 so that the ODNP does not contain the nucleotide at the defined position.
  • the number "n” designates the number of nucleotides within the VRS of the complete IRERS.
  • Methods, kits and compositions of the present invention may involve or include an immobilized ODNP or an array of immobilized ODNPs.
  • the ODNPs of the present invention can be non-covalently immobilized to a substrate.
  • the ODNPs are covalently immobilized to a substrate.
  • the substrate to which the ODNPs of the present invention are immobilized is prepared from a suitable material.
  • the substrate is preferably rigid and has a surface that is substantially flat. In some embodiments, the surface may have raised portions to delineate areas.
  • the suitable material includes, but is not limited to, silicon, glass, paper, ceramic, metal, metalloid, plastics and plastic copolyers.
  • Typical substrates are silicon wafers and borosilicate slides (e.g., microscope glass slides).
  • An example of a particularly useful solid support is a silicon wafer that is usually used in the electronic industry in the construction of semiconductors.
  • the wafers are highly polished and reflective on one side and can be easily coated with various linkers, such as poly(ethyleneimine) using silane chemistry. Wafers are commercially available from companies such as WaferNet, San Jose, CA.
  • an “array” refers to a collection of ODNPs that are placed on a solid support (also referred to "substrate") in distinct areas. Each area is separated by some distance in which no nucleic acid or oligonucleotide is bound or deposited. In some embodiments, area sizes are 20 to 500 microns and the center to center distances of neighboring areas range from 50 to 1500 microns.
  • the array of the present invention may contain 2-9, 10- 100, 101-400, 401-1,000, or more than 1,000 distinct areas.
  • the composition of immobilized molecules of the present array may vary the composition of immobilized molecules of the present array.
  • the ODNPs described above i.e., the immobilized ODNPs useful for producing a portion of a target nucleic acid containing a nucleotide to be identified
  • the ODNPs in a distinct area of an array are homogeneous. More preferably, the ODNPs in every distinct area of an array to which the ODNPs are immobilized are homogeneous.
  • each ODNP molecule in a distinct area has the same sequence as another ODNP molecule in the same area.
  • the ODNPs in at least one of the distinct areas of an array are heterogeneous.
  • heterogeneous indicates that at least one ODNP molecule in a distinct area has a different sequence from another ODNP molecule in the area.
  • molecules other than the ODNPs described above may also be present in some or all of distinct areas of an array. For instance, a molecule useful as an internal control for the quality of an array may be attached to some or all of distinct areas of an array.
  • Such a molecule may be a nucleic acid useful as an indicator of hybridization stringency.
  • the composition of ODNPs in every distinct area of an array is the same.
  • Such an array may be useful in determining genetic variations in a particular gene in a selected population of organisms or in parallel diagnosis of a disease or a disorder associated with mutations in a particular gene.
  • the immobilized ODNPs of the present invention may contain oligonucleotide sequences (i.e., region C and optional region E) complementary to various target nucleic acids.
  • target nucleic acids include, but are not limited to, genes associated with hereditary diseases in animals, oncogenes, genes related to disease predisposition, genomic DNAs useful for forensics and/or paternity determination, genes associated with or rendering desirable features in plants or animals, and genomic or episomic DNA of infectious organisms.
  • An array of the present invention may contain ODNPs complementary to a particular type of target nucleic acids in distinct areas.
  • an array may have an ODNP complementary to a -first gene related to disease predisposition in a first distinct area, another ODNP complementary to a second gene also related to disease predisposition in a second distinct area, yet another ODNP complementary to a third gene also related to disease predisposition in a third distinct area, etc.
  • Such an array is useful to determine disease predisposition of an individual animal (including a human) or a plant.
  • an array may have ODNPs complementary to multiple types of target nucleic acids as to the functions of the targets.
  • an array may contain ODNPs as described above (i.e., the immobilized ODNPs useful for producing a portion of a target nucleic acid containing a nucleotide to be identified) each having the same region D (i.e., the region consisting of a CRS).
  • an array may contain ODNPs having different CRSs, which are part of different IRERSs and thereby recognized by different REs.
  • the immobilized ODNPs must be stable and not dissociate during hybridization, washing or analysis. The density of the immobilized ODNPs must be sufficient for the subsequent
  • ODNP molecules typically 1000 to 10 , preferably 1000 to 10 6 , 10 6 to 10 9 , or 10 9 to 10 12 ODNP molecules are immobilized in at least one distinct area.
  • the immobilization process should not interfere with the ability of immobilized ODNPs to hybridize with target nucleic acids in a sample being analyzed. Thus, it is often best for only one point, ideally the 5' termini of the ODNPs to be immobilized.
  • a linking element i.e., region A of the immobilized ODNP of Figure 19
  • the linking element comprises a chemical chain that serves to distance the other regions of the ODNP from the substrate.
  • the linking elements are cleavable so that the portion of ODNP containing regions C and D detaches from the substrate upon the cleavage of region A.
  • the substrate is coated with a polymeric layer that provides linking elements with a lot of reactive ends/sites.
  • a polymeric layer that provides linking elements with a lot of reactive ends/sites.
  • a common example is glass slides coated with polylysine, which are commercially available.
  • Another example is substrates coated with poly(ethyleneimine) as described in Published PCT Application No. WO99/04896 and U.S. Patent No. 6,150,103.
  • regions C and D of the present ODNP are further distanced from the substrate via region B ( Figure 19).
  • the oligonucleotide portions of the ODNPs i.e., optional region B, regions C and D, and optional region E
  • an ODNP may be immobilized to a substrate in tlie following two ways: (1) synthesizing the ODNP directly on the substrate (often termed “in situ synthesis"), or (2) synthesizing the ODNP separately and then position and bind it to the substrate (sometimes termed "post-synthetic attachmenf).
  • in situ synthesis the primary technology is photolithography. Briefly, the technology involves modifying the surface of a solid support with photolabile groups that protect, for example, oxygen atoms bound to the substrate through linking elements. This array of protected hydroxyl groups is illuminated through a photolithographic mask, producing reactive hydroxyl groups in the illuminated areas.
  • a 3'-O-phosphoramidite-activated deoxynucleoside protected at the 5'-hydroxyl with the same photolabile group is then presented to the surface and coupling occurs through the hydroxyl group at illuminated areas.
  • the substrate is rinsed and its surface is illuminated through a second mask to expose additional hydroxyl groups for coupling.
  • a second 5'-protected, 3'-O- phosphoramidite-activated deoxynucleoside is present to the surface.
  • the selective photo-de-protection and coupling cycles are repeated until the desired set of products is obtained.
  • the post-synthetic attachment approach requires a methodology for attaching pre-existing oligonucleotides to a substrate.
  • One method uses the bio- streptavidin interaction. Briefly, it is well known that biotin and streptavidin form a non-covalent, but very strong, interaction that may be considered equivalent in strength to a covalent bond. Alternatively, one may covalently bind pre-synthesized oligonucleotide to a substrate.
  • carbodiimides are commonly used in three different approaches to couple DNA to solid supports.
  • the support is coated with hydrazide groups that are then treated with carbodiimide and carboxy- modified oligonucleotide.
  • a substrate with multiple carboxylic acid groups may be treated with an amino-modified .
  • Epoxide- based chemistries are also used with amine modified oligonucleotides.
  • Detailed descriptions of methods for attaching pre-existing oligonucleotides to a substrate may be found in the following references: U.S. Patent Nos. 6,030,782; 5,760,130; 5,919,626; published PCT Patent Application No.
  • the primary post-synthetic attachment technologies include ink jetting and mechanical spotting.
  • Ink jetting involves the dispensing of oligonucleotides using a dispenser derived from the ink-jet printing industry. The oligonucleotides are withdrawn from the source plate up into the print head and then moved to a location above the substrate. The oligonucleotides are then forced through a small orifice, causing the ejection of a droplet from the print head onto the surface of the substrate.
  • Mechanical spotting involves the use of rigid pins.
  • the pins are dipped into an oligonucleotide solution, thereby transferring a small volume of the solution onto the tip of the pins. Touching the pin tips onto the substrate leaves spots, the diameters of which are determined by the surface energies of the pins, the oligonucleotide solution, and the substrate.
  • Mechanical spotting may be used to spot multiple arrays with a single oligonucleotide loading. Detailed description of using mechanical spotting in array fabrication may be found in the following patents or published patent applications: U.S. Patent Nos.
  • Methods, kits and compositions of the present invention may involve or include ODNPs (either immobilized or non-immobilized) that are hybridized to a target nucleic acid, where the ODNPs facilitate the production and/or amplification of a defined nucleotide locus witliin the target nucleic acid.
  • ODNPs either immobilized or non-immobilized
  • the ODNPs and target nucleic acid are thus preferably combined under base-pairing condition.
  • hybrids may vary conditions of hybridization to achieve desired degrees of selectivity of ODNP towards target sequence.
  • relatively stringent conditions may be employed to form the hybrids, such as, e.g., low salt and/or high temperature conditions, such as from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C.
  • selective conditions are relatively intolerant of large mismatches between the ODNP target nucleic acid.
  • hybridization of the ODNPs may be achieved under moderately stringent buffer conditions such as, for example, in 10 mM Tris, pH 8.3; 50 mM KC1; 1.5 mM MgCl 2 at 60°C which conditions permit the hybridization of ODNP comprising nucleotide mismatches with the target nucleic acid.
  • moderately stringent buffer conditions such as, for example, in 10 mM Tris, pH 8.3; 50 mM KC1; 1.5 mM MgCl 2 at 60°C which conditions permit the hybridization of ODNP comprising nucleotide mismatches with the target nucleic acid.
  • the ODNPs After being hybridized to the target, the ODNPs are extended with the target or the complement thereof as a template using various methodologies known in the art, such as the polymerase chain reaction (PCR) and modified ligase chain reaction (LCR).
  • PCR polymerase chain reaction
  • LCR modified ligase chain reaction
  • the target nucleic acid is described as a single- stranded nucleic acid below.
  • a double-stranded target nucleic acid may first be denatured to two single-stranded nucleic acids before being mixed with ODNPs.
  • the present invention provides a method to obtain a portion of a target nucleic acid that contains a defined nucleotide locus and a complete IRERS and is immobilized to a substrate.
  • the first primer an immobilized ODNP
  • the second primer a corresponding non-immobilized ODNP
  • the first run of extension is for the first primer having a first CRS to inco ⁇ orate the complement of the nucleotide of interest in the first extension product.
  • the second primer having a second CRS then hybridizes to and extends using the first extension product as a template and thereby inco ⁇ orates the nucleotide of interest and the first CRS in a second extension product.
  • the second extension product then dissociates from the first extension product and re- hybridizes to another first primer molecule that has not extended.
  • the non-extended first primer then extends from a location 3' to the nucleotide of interest in the second extension product, so as to form, in combination with the second extension product, a double-stranded nucleic acid fragment.
  • the double-stranded nucleic acid fragment resulting from the three runs of extensions contains a complete IRERS. « While three runs of extension reactions are sufficient to produce a fragment containing a defined nucleotide locus within a target nucleic acid and a complete IRERS, preferably, more than three extension reactions are conducted to amplify the fragment.
  • the first primer can hybridize to and extend using any of the target nucleic acid, the second extension product, and the complement of the third extension product as a template, as a template.
  • the second primer can hybridize to and extend using either the first extension product or the third extension product as a template.
  • the third extension product and the complement thereof are shorter than any of the target nucleic acid, the first extension product and the second extension product, they are the preferred templates for subsequent extension reactions from either the first or the second ODNPs. This is because the extension efficiency with a short fragment as a template is higher than that with a large fragment as a template. With the increase of the number of extension reactions, the double stranded fragment containing both the nucleotide to be identified and a complete IRERS accumulates more quickly than other molecules in the reaction mixture.
  • the present invention also provides a method to obtain portions of target nucleic acids that contain defined nucleotide loci and complete IRERS s and are immobilized to a substrate. To do so, target nucleic acids are mixed with two sets of ODNPs: a first set that is immobilized to a substrate and thereby form an ODNP array and a second set that is not immobilized to any solid support.
  • Each ODNP of the two sets is designed to inco ⁇ orate a portion of an IRERS (i.e., CRS) as described in detail above so that the extension and/or amplification product of an ODNP of the first set and its corresponding ODNP of the second set contains a complete IRERS. Because the ODNP of the first set and its corresponding ODNP of the second set are complementary to a portion of a target or the complement of the target at a location 3' of a defined position, the extension and/or amplification product from the two ODNPs with the target as a template contains the nucleotide at the defined position.
  • CRS IRERS
  • the extension/amplification reaction can be carried out using any extension/amplification method known in the art, including PCR methods.
  • PCR methods include PCR methods.
  • U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159 all describe PCR methods.
  • PCR methods are also described in several books, e.g., PCR Protocols: Current Methods and Application, edited by Brace A. White, 1993; PCR Primer: A Laboratory Manual, edited by Carl W. Dieffenbach and Gabriela S. Dveksler, 1995; PCR (Basics: From Background to Bench, by McPherson et al.; PCT? Applications: Protocols for Functional Geomics, edited by Michael A.
  • the polymerase will cause the ODNPs to be extended along the target nucleic acid sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended ODNPs will dissociate from the target to form reaction products, excess ODNPs will bind to the target and to the reaction product and the process is repeated.
  • Exemplary PCR conditions according to the present invention may include, but are not limited to, the following: 100 ⁇ l PCR reactions comprise 100 ng target nucleic acid; 0.5 ⁇ M of each first ODNP and second ODNP; 10 mM Tris, pH 8.3; 50 mM KC1; 1.5 mM MgCl 2; 200 ⁇ M each dNTP; 4 units TaqTM DNA Polymerase (Boehringer Mannheim; Indianapolis, IN), and 880 ng TaqStart 7 Antibody (Clontech, Palo Alto, CA).
  • Exemplary thermocycling conditions may be as follows: 94°C for 5 minutes initial denaturation; 45 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; final extension at 72°C for 5 minutes.
  • Exemplary nucleic acid polymerases may include one of the thermostable DNA polymerases that are readily available in the art such as, e.g., TaqTM, VentTM or PFUTM. Depending on the particular application contemplated, it may be preferred to employ one of the nucleic acid polymerases having a defective 3' to 5' exonuclease activity.
  • An alternative way to make and/or amplify a fragment that contains a nucleotide to be identified at a defined position and a complete IRERS and is immobilized to a substrate is by a modified ligase chain reaction, referred to herein as the gap-LCR (Abravaya, et al., Nucleic Acids Res. 23:615-682 (1995)).
  • This method requires four ODNPs ("primer A,” “primer B,” “primer C,” and “primer D”), wherein primer A is immobilized to a substrate.
  • primers A and B will bind to the target located 5' and 3' of (on either side of) the defined position in the target, respectively; whereas primers C and D will bind to the complement of the target located 5' and 3' of the complement of the nucleotide of interest, respectively.
  • primers A and B will bind to the target located 5' and 3' of (on either side of) the defined position in the target, respectively; whereas primers C and D will bind to the complement of the target located 5' and 3' of the complement of the nucleotide of interest, respectively.
  • primers A and B and between primers C and D will be filled in and each pair of primers (i.e., primers A and B, or primers C and D) ligated to form a single unit.
  • bound ligated units dissociate from the target and then serve as "target sequences" for Iigation of excess ODNP pairs.
  • each of the four ODNPs contains a CRS and is spaced from each other to ensure the ligated units contain a complete IRERS.
  • Gap-LCR may be used to produce immobilized fragments that contain nucleotides to be identified within target nucleic acids and complete IRERSs in parallel.
  • an array of primer As is used in combination of sets of primer Bs, Cs and Ds.
  • Each primer A on the array will make and/or amplify a portion of a target nucleic acid that further contains a complete IRERS in the presence of its corresponding primers B, C and D, a polymerase, and a ligase. Accordingly, multiple immobilized fragments will be obtained that contain portions of target nucleic acids with different sequences.
  • gap-LCR uses both a nucleic acid polymerase enzyme and a nucleic acid ligase enzyme to drive the reaction.
  • exemplary nucleic acid polymerases may include one of the thermostable DNA polymerases that are readily available in the art such as, e.g., TaqTM, VentTM or PFUTM.
  • Exemplary nucleic acid ligases may include T4 DNA ligase, or the thermostable Tsc or Pfu DNA ligases.
  • U.S. Patent No. 4,883,750 inco ⁇ orated herein by reference in its entirety, describes an alternative method of amplification similar to LCR for binding ODNP pairs to a target sequence.
  • Exemplary gap-LCR conditions may include, but are not limited to, the following: 50 ⁇ l LCR reactions comprise 500 ng DNA; a buffer containing 50 mM EPPS, pH 7.8, 30 mM MgCl 2 , 20 mM K + , 10 ⁇ M NAD, 1-10 ⁇ M gap filling nucleotides, 30 nM each oligonucleotide primer, 1 U Thermusflavus DNA polymerase, lacking 3'->5' exonuclease activity (MBR, Milwukee, WI), and 5000 U T. thermophilus DNA ligase (Abbott Laboratories). Cycling conditions may consist of a 30 s incubation at 85°C and a 30 s incubation at 60°C for 25 cycles and may be carried out in a standard PCR machine such as a Perkin Elmer 9600 thermocycler.
  • a number of other template dependent methodologies may be used either to amply target nucleic acids before combining the target nucleic acids with the ODNPs of the present invention.
  • such methodologies may be used, in combination of the immobilized ODNPs or the array of ODNPs described above, to produce a fragment containing a portion of a target nucleic acid with a defined nucleotide locus and a complete IRERS.
  • Qbeta Replicase described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880, inco ⁇ orated herein by reference in its entirety, may alternatively be used with methods of the present invention.
  • RNA polymerase a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase.
  • the polymerase will copy the replicative sequence that can then be detected.
  • Strand Displacement Amplification SDA
  • SDA Strand Displacement Amplification
  • RCR Repair Chain Reaction
  • nucleic acid amplification procedures include transcription-based amplification systems (TAS) (also referred to as transcription-mediated amplification, or TMA) (Kwoh et al, 1989; PCT Intl. Pat. Appl. Publ. No. WO 88/10315, inco ⁇ orated herein by reference in its entirety), including nucleic acid sequence based amplification (NASBA) and 3SR.
  • TAS transcription-based amplification systems
  • NASBA nucleic acid sequence based amplification
  • 3SR nucleic acid sequence based amplification
  • the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA.
  • RNAs are reverse transcribed into DNA, and transcribed once again with a polymerase such as T7 or SP6.
  • ssRNA single-stranded RNA
  • dsDNA double-stranded DNA
  • the ssRNA is a first template for a first ODNP, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase).
  • RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA).
  • RNase H ribonuclease H
  • the resultant ssDNA is a second template for a second ODNP, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its template.
  • This ODNP is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of E.
  • dsDNA double-stranded DNA
  • This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.
  • hybridization and amplification conditions for reactions involving immobilized ODNPs are similar to those involving ODNPs in solution.
  • One of ordinary skill in the art would be able to optimize those conditions in view of a particular ODNP and its corresponding target nucleic acid.
  • Exemplary hybridization and/or amplification conditions may be found in U.S. Patent Nos. 6,013,449, 6,156,502, 5,858,659, 5,424,186, 5,902,723, 6,045,996, 6,087,112, 6,156,501 and published PCT Patent Applications Nos. WO92/10092, 95/11995. All of these patents or patent applications are inco ⁇ orated herein by reference.
  • Methods, kits and compositions of the present invention typically involve or include one or more interrupted restriction endonucleases.
  • restriction endonuclease refers to the class of nucleases that bind to unique double-stranded nucleic acid sequences and that generate a cleavage in the double- stranded nucleic acid that results in either blunt, double stranded ends, or single stranded ends with either a 5' or a 3' overhang.
  • IRERS interrupted restriction endonuclease recognition sequence
  • first CRS also referred to as “Region D”
  • second CRS a restriction endonuclease recognition site
  • VRE variable recognition sequence
  • “Second CRS” (also referred to as “Region S”) is defined as that region of the IRERS that contains the constant (not variable) nucleotides of the IRERS that are located 3' of the VRE of the IRERS.
  • the "VRE” (also referred as “Region N”) is defined as the stretch of one or more variable nucleotides that are located between the first and second CRSs.
  • the term “Bsl I” refers to an exemplary RE that binds to a unique nucleic acid sequence that is composed of 5'-CCNNNNNNNGG-3' where N is an undefined nucleotide base or analog thereof, and that cleaves double-stranded nucleic acid.
  • the cleavage site is as follows:
  • the base to be identified e.g., the mutation or SNP
  • the base to be identified is positioned within the middle three "Ns" comprising the 3 'overhang.
  • the base to be identified is positioned within the 6 th nucleotide from the 5' end of the top strand.
  • the base to be identified may be at any other positions within the variable recognition sequence.
  • EcoN I refers to another exemplary RE that binds to a unique nucleic acid sequence composed of 5'-CCTNNNNNAGG-3' (SEQ ID NO. 3) where N is an undefined nucleotide base or analog thereof, and that cleaves double-stranded nucleic acid.
  • the cleavage site is as follows:
  • the base to be identified is positioned at the 6 th nucleotide from the 5' end of the top strand.
  • Any restriction endonuclease that recognizes an interrupted restriction endonuclease recognition sequence can be used in the present invention.
  • Some of such enzymes are commercially available from numerous companies such as, e.g., New England Biolabs Inc. (Beverly, MA; www.neb.com); Stratagene (La Jolla, CA; www.stratagene.com), Promega (Madison, WI: www.promega.com), and Clontech (Palo Alto, CA; www.clontech.com).
  • Non-commercially available restriction enzymes may be isolated and/or purified based on the teaching available in the art.
  • restriction enzyme ApaB I restriction enzyme
  • Grones and Tuma Biochim. Biophys. Ada 1162:323-325 (1993), Grones and Turna
  • Biologia Biologia (Bratisl) 46:1103-1108 (1991); for EcoH I, Glatman et al., Mol. Gen. Mikrobiol. Virusol. 3:32 (1990); for Fmu I, Rebentish et al. Biotekhnologiya 3:15-16 (1994); for HpyB II, FEMS Microbial. Lett.
  • REs suitable for use in the present invention and their corresponding recognition sequences are presented in Table 1. It will be apparent to one of ordinary skill in the art, however, that REs available in the art that recognizes IRERSs, but are not included in Table 1, may be equally suitable depending on the particular application contemplated.
  • a nucleic acid fragment containing a portion of target nucleic acid with a defined nucleotide locus and a complete IRERS is digested (or cleaved) by a RE that recognizes the IRERS.
  • Conditions for storage and use of restriction endonucleases used according to the present invention are readily available in the art, for example, by reference to one of the laboratory manuals such as Sambrook et al., supra and Ausubel et al., supra. Briefly, the number of units of IPRE added to a reaction may be calculated and adjusted according to the varying cleavage rates of nucleic acid substrates.
  • restriction endonuclease 1 unit of restriction endonuclease will digest 1 ug of substrate nucleic acid in a 50 ⁇ l reaction in 60 minutes. Generally, fragments (e.g., amplicons) may require more than 1 unit/ug to be cleaved completely.
  • the restriction enzyme buffer is typically used at IX concentration in the reaction.
  • Some restriction endonucleases require bovine serum albumin (BSA) (usually used at a final concentration of 100 ⁇ g/ml for optimal activity). Restriction endonucleases that do not require BSA for optimal activity are not adversely affected if BSA is present in the reaction.
  • BSA bovine serum albumin
  • the immobilized extension amplification products described above may be digested by different REs that recognize various IRERSs of which the CRSs of the ODNPs are components, if the digestion conditions for the REs are similar. However, if the different REs can not function well together, they may be applied to the array sequentially. Between each run of digestion, the buffer for a previous RE will be washed off the array, and the array will then be put into another buffer suitable for a next RE. Most restriction enzymes are stable when stored at -20°C in the recommended storage buffer. Exposure to temperatures above -20°C should be minimized whenever possible. All restriction endonucleases should be kept on ice when not otherwise being stored in the freezer.
  • Enzymes should always be the last component added to a reaction.
  • the recommended incubation temperature for most restriction endonucleases is about 37°C.
  • Restriction endonucleases isolated from thermophilic bacteria require higher incubation temperatures, typically ranging from 50°C to 65°C.
  • Incubation time may often be shortened if an excess of restriction endonuclease is added to the reaction. Longer incubation times are often used to allow a reaction to proceed to completion with fewer units of restriction endonuclease.
  • the present invention provides methodology whereby a fragment is cleaved using a restriction endonuclease, so as to generate a short (also referred to as "small") nucleic acid fragment.
  • This short nucleic acid fragment contains information which, upon characterization of the fragment, allows one to determine the identity of the nucleotide(s) of interest in the target nucleic acid.
  • the present invention transfers information about the nucleotide(s) of interest from a relatively large target nucleic acid into a relatively small nucleic acid fragment.
  • the nucleotide(s) of interest is made to constitute a relatively large portion of the bases in a nucleic acid, such that characterization of the nucleic acid (fragment) is more readily able to reveal information about the nucleotide(s) of interest.
  • a direct and complete characterization of the small nucleic acid fragment can be obtained (which is often practically impossible for a large target nucleic acid) which will reveal the identity of the nucleotide(s) of interest.
  • methods according to the present invention employ, inter alia, the steps of using appropriate primer(s) and a target nucleic acid to prepare an intermediate structure (e.g., an amplicon) that is digested with a suitable restriction endonuclease to produce one or more small nucleic acid fragments.
  • an intermediate structure e.g., an amplicon
  • One or more of these fragments is then characterized to obtain partial or complete base sequence information about the fragment, including identification of the nucleotide(s) of interest in the target nucleic acid.
  • any digestion product that contains the nucleotide(s) at a defined location or the complement thereof may be characterized to determine the identity of the nucleotide(s).
  • the nucleotide and/or its complement may reside in a digestion product immobilized to a substrate.
  • the nucleotide and/or its complement may be in a digestion product in solution.
  • immobilized digestion products double-stranded
  • a product having the complement of the nucleotide of interest within a 3' overhang Figure 21, panel A
  • a product having the nucleotide of interest within a 5' overhang Figure 21, panel B
  • a product having both the nucleotide of interest and its complement Figure 21, panel C
  • the first and second products are resulted from digestions of REs that produce a 3' overhang and a 5' overhang, respectively.
  • the third product can be resulting from a digestion of a RE that produces any of the following ends: a 3' overhang, a 5' overhang and a blunt end.
  • the present invention allows the characterization of digestion products either on a solid substrate (i.e., for the immobilized digestion products) or in solution (i.e., for the non-immobilized digestion products).
  • the immobilization of half of the digestion products eliminates, or reduces the extent of, fractionation needed before the characterization.
  • oligonucleotide (a) i.e., the immobilized strand that contains the first ODNP
  • oligonucleotide (b) i.e., the complementary strand of oligonucleotide (a)
  • Figure 21 the characterization of oligonucleotide (a) (i.e., the immobilized strand that contains the first ODNP) does not require any fractionation steps prior to its characterization as both the non-immobilized double-stranded digestion product and oligonucleotide (b) (i.e, the complementary strand of oligonucleotide (a)) may be washed off the substrate to which oligonucleotide (a) is bound after denaturation (Figure 21).
  • oligonucleotide (b) does not require any fractionation steps as oligonucleotide (b) can be separated from the non-immobilized double-stranded digestion product by washing off the substrate to which oligonuleotide (b) is bound via its base-pairing with oligonucleotide (a) and further separated from oligonucleotide (a) by denaturation.
  • oligonucleotide (c) i.e., the non-immobilized strand that was a portion of an extension product of the first ODNP
  • its complementary strand oligonucleotide (d) may not need to be separated from each other before their characterization in certain embodiments. Even if separation is necessary in some other embodiments, the immobilization of oligonucleotides (a) and (b) simplifies the separation process as two, instead of four, single-stranded oligonucleotides need to be fractionated.
  • the array may be designed to physically separate areas that contain different digestion products from each other. Any partitioning means suitable for this pu ⁇ ose may be used. For instance, the array may have raised portions to delineate distinct areas. Alternatively, the array may have lowered portions (e.g., wells as in microtiter plates) to define distinct areas.
  • the digestion products that are not immobilized prior to their characterization include oligonucleotides (c) and (d), oligonucleotide (b) after its dissociation from oligonucleotide (a), and oligonucleotide (a) containing a cleavable linking element after its cleavage.
  • the characterization of a nucleic acid fragment i.e., a digest product
  • the present invention transfers information about nucleotide(s) of interest from a relatively large target nucleic acid into a relatively small nucleic acid fragment. Such information transfer allows direct characterization of the small fragment in many instances. For example, small nucleic acid fragments are amenable to direct detection by a variety of mass spectrometric methodologies (as discussed herein below) as well as by ultraviolet (UV) abso ⁇ tion.
  • the complete nucleotide sequence will be known for the short nucleic acid fragment even before it is formed.
  • the issue then becomes detecting the nucleotide of interest over the "noise" created while concurrently detecting the other bases.
  • this signal can be subtracted from the overall signal for the fragment, to leave information about the nucleotide of interest.
  • This approach is essentially adopted in using mass spectrometry to characterize the small nucleic acid fragment.
  • Other suitable methods include determining the mass-to-charge ratio of the small nucleic acid fragment(s), by measuring fluorescence polarization and/or by quantifying ultraviolet (UV) abso ⁇ tion.
  • characterizing a small nucleic acid fragment may entail simply determining the sizes of these single-strand fragments, and from this information the skilled artisan can deduce whether a target nucleic acid contains one or more mutations at a defined nucleotide locus. It will be apparent that the size of a single- strand fragment may be determined by numerous methods that are readily available in the art.
  • Exemplary methods disclosed herein including methods for measuring the size and/or molecular weight of a single-strand nucleic acid fragment, include, but are not limited to fluorescence including fluorescence polarization (FP), mass spectrometry (MS), ultraviolet (UV) abso ⁇ tion, cleavable mass tags, TaqMan (homogeneous), fluorescence resonance energy transfer (FRET), colorimetric, luminescence and/or fluorescence methodologies employing substrates for horseradish peroxidase (HRP) and/or alkaline phosphatase (AP), as well as methods employing radioactivity.
  • FRET fluorescence resonance energy transfer
  • MS may be employed for characterizing a strand of a small (short) nucleic acid fragments comprising the nucleotide locus of the target nucleic acid.
  • MS may be particularly advantageous in those applications in which it is desirable to eliminate a fractionation step prior to detection.
  • MS may also be employed in conjunction with a fractionation methodology, as discussed herein below, such as, for example, one of the liquid chromatography methodologies including HPLC and DHPLC.
  • MS detection does not require the addition of a tag or label to the small nucleic acid fragment. Instead, the nucleic acid fragment can be identified directly in the mass spectrometer.
  • MS may be particularly suitable to the detection of small nucleic acid fragments from as small as 1 nucleic acid to as large as several hundred nucleotides. More preferable are fragments of 1 to 50 nucleotides, still more preferable are fragments of from 1 to 14 nucleotides.
  • Sensitivities may be achieved to at least to 1 amu.
  • the smallest mass difference in nucleic acid bases is between adenine and thymidine, which is 9 Daltons.
  • LC-TOF-MS Chromatography-Time-of-Flight Mass Spectrometry
  • LC-TOF-MS is composed of an orthogonal acceleration Time-of-Flight (TOF) MS detector for atmospheric pressure ionization (API) analysis using electrospray (ES) or atmospheric pressure chemical ionization (APCI).
  • TOF-MS provides high mass resolution (5000 FWHM), high mass measurement accuracy (to within 5ppm) and very good sensitivity (ability to detect picomolar amount of DNA polymer) compared to scanning quadrupole instruments.
  • TOF instruments are generally more sensitive than quadrupoles, but correspondingly more expensive.
  • LC-TOF-MS has a more efficient duty cycle since the current instruments can sequentially analyze one mass at a time while rejecting all others (this is referred to as single ion monitoring (SIM)).
  • SIM single ion monitoring
  • LC-TOF-MS samples all of the ions passing into the TOF analyzer at the same time. This results in higher sensitivity and provides quantitative data which improves the sensitivity between 10 and 100 fold.
  • Enhanced resolution (5000 FWHM) and mass measurement accuracy of better than 5 ppm imply that differences between nucleosides as small as 9 amu (Daltons) can be accurately measured.
  • the TOF mass analyzer performs very high frequency sampling (10 spectra/sec) of all ions simultaneously across the full mass range of interest.
  • the duty cycle of the LC-TOF-MS allows high sensitivity spectra to be recorded in quick succession making the instrument compatible with more efficient separation techniques such as narrow bore LC, capillary chromatography (CE) and capillary electrochromatography (CEC).
  • CE capillary chromatography
  • CEC capillary electrochromatography
  • aerosol spray is directed pe ⁇ endicularly past the sampling cone, which is displaced from the central axis of the instrument. Ions are extracted orthogonally from the spray into the sampling cone aperture leaving large droplets, involatile materials, particulates and other unwanted components to collect in the vent port that is protected with an exchangeable liner.
  • the second orthogonal step enables the volume of gas (and ions) sampled from atmosphere to be increased compared with conventional API sources. Gas at atmospheric pressure sampled through an aperture into a partial vacuum forms a freely expanding jet, which represents a region of high performance compared to the surrounding vacuum. When this jet is directed into the second aperture of a conventional API interface it increases the flow of gas through the second aperture.
  • Maintaining a suitable vacuum in the MS- TOF therefore places a restriction on the maximum diameter of the apertures in such an LC interface. Ions in the partial vacuum of the ion block are extracted electrostatically into the hexapole ion bridge which efficiently transports ions to the analyzer.
  • LC-TOF-MS The coupling of the TOF mass analyzers with MUX-technology allows the connection of up to 8 HPLC columns in parallel to a single LC-TOF-MS. (Micromass, Manchester UK).
  • a multiplexed electrospray (ESI) interface is used for on-line LC-MS utilizing an indexed stepper motor to sequentially sample from up to 8 HPLC columns or liquid inlets operated in parallel.
  • ESI electrospray
  • Use of LC-TOF-MS is generally preferred over use of MALDI-TOF because LC-TOF-MS is a quantitative method for analysis of the molecular weight of polymers.
  • LC-TOF-MS does not fragment the polymers and it employs a very gentle ionization process compared to matrix-assisted-lazer-deso ⁇ tion-ionization (MALDI). Because every MALDI blast is different, the ionization is not quantitative. LC-TOF- MS does, however, produce different m/z values for polymers, but, as disclosed in Example 1 and Figures 1-9, this property provides the additional advantage of reducing background and providing complementary information.
  • MALDI matrix-assisted-lazer-deso ⁇ tion-ionization
  • Tandem MS or MS/MS is used for structure determination of molecular ions or fragments.
  • the ion of interest is selected with the first analyzer (MS-1), collided with inert gas atoms in a collision cell, and the fragments generated by the collision are separated by a second analyzer (MS-2).
  • MS-1 first analyzer
  • MS-2 second analyzer
  • Ion Trap and Fourier transform experiments the analyses are carried out in one analyzer, and the various events are separated in time, not in space. The information can be used to sequence peptides and small DNA/RNA oligomers.
  • Exact mass measurements are used for elemental-composition determination > of the sample molecular ion or an ionic fragment.
  • the basis of the method is that each element has a unique mass defect (deviation from the integer mass).
  • the measurement is carried out by scanning with an internal calibrant (in El or CI mode) or by peak matching (in FAB mode).
  • the elemental composition is determined by comparing the masses of many possible compositions to the measured one.
  • the method is very reliable for samples having masses up to 800 Da. At higher masses, higher precision or knowledge of expected composition are required to determine the elemental composition unambiguously.
  • Electron ionization (El) is widely used in mass spectrometry for relatively volatile samples that are insensitive to heat and have relatively low molecular weight.
  • the spectra are useful for structural characterization and identification. Small impurities in the sample are easy to detect.
  • Chemical ionization (CI) is applied to similar samples; it is used to enhance the abundance of the molecular ion.
  • the molecular weight range is 50 to 800 Da. h rare cases it is possible to analyze samples of higher molecular weight. Accuracy of the mass measurement at low resolving power is ⁇ 0.1 Dalton and in the high resolution mode, ⁇ 5 ppm.
  • FAB Fast atom bombardment ionization
  • LSIMS liquid secondary ionization MS
  • the spectram often contains peaks from the matrix, which is necessary for ionization, a few fragments and a peak for a protonated or deprotonated sample molecule.
  • FAB is used to obtain the molecular weight of sensitive, nonvolatile compounds. The method is prone to suppression effects by small impurities. The molecular weight range is 100 to 4000 Da.
  • Exact mass measurement is usually done by peak matching. The accuracy of the mass is the same as obtained in El, CI.
  • Matrix-assisted laser deso ⁇ tion has been used to determine the molecular weight of peptides, proteins, oligonucleotides, and other compounds of biological origin as well as of small synthetic polymers.
  • the amount of sample needed is very low (pmoles or less).
  • the analysis can be performed in the linear mode (high mass, low resolution) up to a molecular weight of m/z 300,000 (in rare cases) or reflectron mode (lower mass, higher resolution) up to a molecular weight of 10,000.
  • the analysis is relatively insensitive to contaminants, and accordingly a purification step is not necessarily a part of the characterization process when characterization includes MS. Mass accuracy (0.1 to 0.01%) is not as high as for other mass spectrometry methods. Recent development in Delayed Extraction TOF allows higher resolving power and mass accuracy.
  • Electrospray ionization allows production of molecular ions directly from samples in solution. It can be used for small and large molecular-weight biopolymers (peptides, proteins, carbohydrates, and DNA fragments), and lipids. Unlike MALDI, which is pulsed, it is a continuous ionization method that is suitable for using as an interface with HPLC or capillary electrophoresis. Multiply charged ions are usually produced. ESI should be considered a complement to MALDI. The sample must be soluble, stable in solution, polar, and relatively clean (free of nonvolatile buffers, detergents, salts, etc.). Electron-capture (sometimes called negative ion chemical ionization or
  • NICI NICI
  • analyte is derivatized to contain highly electron-capturing moieties (e.g., fluorine atoms or nitrobenzyl groups).
  • moieties are generally inserted into the target analyte after isolation and before mass spectrometric analysis.
  • the sensitivity of NICI analyses is generally two to three orders of magnitude greater than that of PCI or El analyses. Little fragmentation occurs during NICI.
  • a detectable label to a short nucleic acid fragment or the reaction product thereof (e.g., a portion or the whole complementary strand of the short nucleic acid fragment).
  • Such labels facilitate the characterization of the fragment and thereby the identification of nucleotide(s) of interest and/or genetic variations within the fragment.
  • Tables 2 and 3 summarize exemplary labels and detectors, respectively, that are generally suitable for use in methodologies for detecting small nucleic acid fragments.
  • Fluorescent plate reader Reliable, inexpensive, sensitive, multicolor
  • Fluorescence Polarization Permits homogeneous assay formats, some instruments very sensitive.
  • Detectors for these tags and labels are available in generic and non- generic instruments.
  • the generic instruments are the plate readers that usually read micro-plates in 96-well or 384-well formats, and are capable of reading multiple colors (4-6 fluorescent tags). These instruments can be found in customized versions to perform more specialized measurements like time-resolyed-fluorescence (TFR) or fluorescence polarization.
  • TFR time-resolyed-fluorescence
  • the detectors for PAGE sequencing and bundled capillary instruments are highly dedicated and non-generic.
  • the generic mass spectrometers MALDI-TOF, electrospray-TOF and APCI-quadrupole (and combinations thereof including ion-trap instruments) are opened-ended instruments with versatility. Suitable software packages have been developed for combinatorial chemistry applications. Scintillation counters are dedicated in that they need to be used with radioisotopes, but can accommodate a wide range of assays formats.
  • the present invention is not limited to these examples. Any techniques known in the art suitable for characterizing small nucleic acid fragments and thereby determining the identity of nucleotide(s) at a defined location may be used in the present invention.
  • a nucleic acid fragment i.e., a digestion product described above
  • a nucleic acid fragment is characterized by performing a complete nucleotide sequence analysis.
  • Many techniques are known in the art for identifying each of the bases in a nucleic acid fragment, so as to obtain base sequence information. For instance, two different DNA sequencing methodologies that were developed in 1977, and are commonly known as “Sanger sequencing” and “Maxam Gilbert sequencing,” among other names, are still in wide use today and are well known to those of ordinary skill in the art. See, e.g., Sanger, Proc. Natl. Acad. Sci. (USA) 74:5463, 1977) and Maxam and Gilbert, Proc. Natl. Acad. Sci. (USA) 74:560, 1977).
  • Both methods produce populations of shorter fragments that begin from a particular point and terminate in every base that is found in the nucleic acid fragment that is to be sequenced.
  • the shorter nucleic acid fragments are separated by polyacrylamide gel electrophoresis and the order of the DNA bases (adenine, cytosine, thymine, guanine; also known as A,C,T,G, respectively) is read from a autoradiograph of the gel.
  • Automated DNA sequencing methods may also be used. Such methods are in wide-spread commercial use to sequence both long and short nucleic acid molecules. In one approach, these methods use fluorescent-labeled primers or ddNTP- terminators instead of radiolabeled components.
  • Robotic components can utilize polymerase chain reaction (PCR) technology which has lead to the development of linear amplification strategies.
  • PCR polymerase chain reaction
  • Current commercial sequencing allows all 4 dideoxy- terminator reactions to be run on a single lane. Each dideoxy-terminator reaction is represented by a unique fluorescent primer (one fluorophore for each base type: A, T, C, G). Only one template DNA (i.e., DNA sample) is represented per lane.
  • Current gels permit the simultaneous electrophoresis of up to 64 samples in 64 different lanes.
  • Different ddNTP-terminated fragments are detected by the irradiation of the gel lane by light followed by detection of emitted light from the fluorophore.
  • Each electrophoresis step is about 4-6 hours long.
  • Each electrophoresis separation resolves about 400-600 nucleotides (nt), therefore, about 6000 nt can be sequenced per hour per sequencer.
  • Gilbert has described an automated DNA sequencer (EPA, 92108678.2) that consists of an oligomer synthesizer, an array on a membrane, a detector which detects hybridization and a central computer.
  • the synthesizer synthesizes and labels multiple oligomers of arbitrary predicted sequence.
  • the oligomers are used to probe immobilized DNA on membranes.
  • the detector identifies hybridization patterns and then sends those patterns to a central computer which constructs a sequence and then predicts the sequence of the next round of synthesis of oligomers.
  • a DNA sequence can be obtained in an automated fashion. This approach may be used to characterize a short nucleic acid fragment (either double or, more commonly single stranded) according to the present invention.
  • Sequencing nucleic acids with ⁇ 100 bases by the common enzymatic ddNTP technique is more complicated than it is for larger nucleic acid templates, so that chemical degradation is sometimes employed.
  • the chemical decomposition method requires about 50 pmol of radioactive 32 P end-labeled material, 6 chemical steps, electrophoretic separation, and film exposure.
  • ESI electrospray ionization
  • FT Fourier transform
  • MS mass spectrometry
  • Dissociation products of multiply-charged ions measured at high (105) resolving power represent consecutive backbone cleavages providing the full sequence in less than one minute on sub-picomole quantity of sample (Little et al., J. Am. Chem. Soc. 116:4893, 1994).
  • ESI/MS has been extended to larger fragments (Potier et al., Nuc. Acids Res. 22:3895, 1994).
  • ESI/FTMS appears to be a valuable complement to classical methods for sequencing and pinpoint mutations in nucleotides as large as 100-mers.
  • FP is based on the property that when a fluorescent molecule is excited by plane-polarized light, it emits polarized fluorescent light into a fixed plane if the tagged-molecules do not significantly rotate between excitation and emission. If the molecule is small enough and rotates and tumbles in space, however, fluorescence polarization is not observed fully by the detector.
  • the fluorescence polarization of a molecule is proportional to the molecule's rotational relaxation time (usually the time it takes to rotate through an angle of 68.5°), which is related to properties of the solution such as the viscosity, temperature, and molecular volume of the analyte or biomolecule.
  • fluorescence polarization is directly proportional to molecular volume, which, in turn, is directly proportional to molecular weight. Larger tagged molecules rotate and tumble slowly in space and, accordingly, fluorescence polarization values can be obtained. In contrast, smaller molecules rotate and tumble faster and fluorescence polarization cannot be measured.
  • the present invention exploits the property that small nucleic acid fragments tumble slowly in solution and, consequently, are amenable to detection by fluorescence polarization.
  • fluorescent-tagged-nucleoside triphosphates including dideoxyribonucleoside triphosphates (ddNTPs), deoxyribonucleoside triphosphates (DNTPs) and ribonucleoside triphosphates (rNTPs)
  • ddNTPs dideoxyribonucleoside triphosphates
  • DNTPs deoxyribonucleoside triphosphates
  • rNTPs ribonucleoside triphosphates
  • fluorescent-tagged- nucleoside triphosphates are made detectable by their inco ⁇ oration into small nucleic acid fragments.
  • the methods described herein may be performed homogenously in a single vessel and may employ a nucleotide fill-in reaction wherein a labeled deoxynucleoside or ribonucleoside is inco ⁇ orated into the end of the small nucleic acid fragment.
  • the target nucleic acid of interest may be amplified from a population of nucleic acids from a biological sample and the resulting amplicon incubated with a RE, e.g., EcoN I thereby generating two fragments with recessed 3' ends.
  • the nucleotide of interest i.e., a genetic variation
  • its complement is located within a 5' overhang (i.e., oligonulceotides (b) and (c) of Figure 21, panel (B))
  • fluorescent-labeled nucleotide(s) are inco ⁇ orated into the complement of the nucleic acid fragment containing the nucleotide of interest or its complement nucleotide by a fill-in reaction.
  • the fill-in reaction is performed in the presence of allele-specific dye-labeled ddNTPs and a commercially available modified Taq DNA polymerase.
  • An alternative preferable method to inco ⁇ orate fluorescent label is to use a RNA polymerase to fill in a recessed 3' end with fluorescent-labeled rNTPs.
  • a fill-in reaction eliminates the need of using alkaline phosphatase to dephosphorylate all the existing dNTPs.
  • alkaline phosphatase must be used to dephosphorylate all the existing dNTPs to permit the efficient inco ⁇ oration of the ddNTPs.
  • the fill-in reaction places the fluorescent-labeled nucleoside specific for the allele of the template, increasing about 20-fold the molecular weight of the fluorophore.
  • the fluorescence polarization of the resulting fluorescent-label oligonucleotides, as well as remaining fluorescent-labeled nucleoside triphosphates, in the reaction mixture is analyzed directly without separation or purification.
  • FPIAs fluorescence polarization immunoassays
  • Fluorescent dyes are identified and quantified most directly by their abso ⁇ tion and fluorescence emission wavelengths and intensities. Emission spectra (fluorescence and phosphorescence) are much more sensitive and specific than abso ⁇ tion spectra. Other photophysical characteristics (like fluorescence anisotropy) are less widely used.
  • the useful intensity parameters are quantum yield (QY) for fluorescence, and the molar extinction coefficient ( ⁇ ) for abso ⁇ tion. QY is a measure of the total photon emission over the entire fluorescence spectral profile and the value of ⁇ is specified at a given wavelength (usually the abso ⁇ tion maximum of the probe).
  • a narrow optical bandwidth ( ⁇ 25 nm) is usually used for fluorescence excitation (via abso ⁇ tion), whereas the fluorescence detection bandwidth is more variable, ranging from full spectrum for maximal sensitivity to narrow band ( ⁇ 20 nm) for maximal resolution.
  • Fluorescence intensity per probe molecule is proportional to the product of ⁇ and QY.
  • Commercially important and exemplary fluorochromes that are widely used are fluorescein, tetramethylrhodamine, lissamine, Texas Red and BODIPYs.
  • Fluorescent labels are now commonly used for the detection of small nucleic acid fragments that have been separated by capillary electrophoresis (CE) or high- performance liquid chromatography (HPLC).
  • One group of labels that may be employed for this pu ⁇ ose are those based on near-infrared (near-IR) fluorescent dyes. In aqueous solution, these types of tags have a maximum abso ⁇ tion of light at >680 nm, followed by the emission of fluorescence at near-IR wavelengths (emission maximum, >700 nm).
  • One advantage of using this type of fluorescence for detection is that it occurs in a spectral region where there is relatively little abso ⁇ tion or emission due to other compounds that might be present in biological samples. This, plus the fact that most near IR probes can be excited with commercially available lasers, provides this approach with low background signals and limits of detection that extend into the attomole range.
  • fluorescence One of the limitations of fluorescence is the phenomenon of autofluorescence.
  • An elegant method to avoid autofluorescence is to employ fluorochromes that possess significantly longer delay times to emission (see Fernandes for review). These fluorochromes are usually luminescent metal chelates that are attached at the 5 '-end of an ODN probe or primer.
  • Time-resolved fluorescence spectroscopy is particularly useful in structural biology and is used to monitor molecular interactions and motions that occur in the picosecond-nanosecond time range. Time-resolved fluorescence spectroscopy is beginning to dominate the analysis of biomolecular structure and dynamics.
  • Deoxyribonucleoside analogs that may be inco ⁇ orated into a small nucleic acid fragment of the present invention, to thereby afford an effective characterization means for the small nucleic acid, include but are not limited to: Fluorescein- 12-dUTP, Coumarin-5-dUTP, Tetramethylrhodamine-6-dUTP, Texas Red ® - 5-dUTP, Napthofluorescein-5-dUTP, Fluorescein Chlorotriazinyl-4-dUTP, Pyrene-8- dUTP, Diethylaminocoumarin-5-dUTP,Cyanine 3-dUTP, Cyanine 5-dUTP, Coumarin-5- dCTP, Fluorescein-12-dCTP, Tetramethylrhodamine-6-dCTP, Texas Red ® -5-dCTP, LissamineTM-5-dCTP, Napthofluorescein-5-dCTP, Fluorescein Chlorotriazinyl-4
  • Ribonucleoside analogs include but are not limited to: Fluorescein- 12- UTP, Coumarin-5-UTP, Tetramethylrhodamine-6-UTP, Texas Red ® -5-UTP, LissamineTM-5-UTP, Napthofluorescein-5-UTP, Fluorescein Chlorotriazinyl-4-UTP, Pyrene-8-UTP, Cyanine 3-UTP, Cyanine 5-UTP, Coumarin-5-CTP, Fluorescein- 12-CTP, Tetramethylrhodamine-6-CTP, Texas Red ® -5-CTP. LissamineTM-5-CTP,
  • Napthofluorescein-5-CTP Fluorescein Chlorotriazinyl-4-CTP, Pyrene-8-CTP, Cyanine 3-CTP, Cyanine 5-CTP, Coumarin-5-ATP, Fluorescein- 12- ATP, Tetramethylrhodamine- 6-ATP, Texas Red ® -5-ATP, LissamineTM-5-ATP, Coumarin-5-GTP, Fluorescein- 12-GTP, Tetramethylrhodamine-6-GTP, Texas Red ® -5-GTP, LissamineTM-5-GTP.
  • Dideoxy analogs include but are not limited to: Fluorescein- 12-ddUTP, FAM-ddUTP, ROX-ddUTP, R6G-ddUTP, TAMRA-ddUTP, JOE-ddUTP, RllO-ddUTP, Fluorescein- 12-ddCTP, FAM-ddCTP, ROX-ddCTP, R6G-ddCTP, TAMRA-ddCTP, JOE-ddCTP, RllO-ddCTP, Fluorescein- 12-ddGTP, FAM-ddGTP, ROX-ddGTP, R6G- ddGTP, TAMRA-ddGTP, JOE-ddGTP, RllO-ddGTP, Fluorescein- 12-ddATP, FAM- ddATP, ROX-ddATP, R6G-ddATP, TAMRA-ddATP, JOE-ddATP, RllO-ddATP
  • Analogs can also be un-natural nucleoside analogs including, but not limited to, the following: 8-Bromo-2'-deoxyadenosine-TTP, 8-Oxo-2'-deoxyadenosine, Etheno-2'-deoxyadenosine-TTP, Etheno-2'-deoxyadenosine-TTP, N 6 -Methyl-
  • the above method may also be useful for determining whether the organism from which the targets are isolated contains homozygous wild type alleles, two or more variant alleles, or both wild type and variant alleles (i.e., heterozygous alleles). Such determination is due to the fact that different fluorophores may be used to label nucleotide specific to a wild type allele and various variant alleles. For instance, the detection of the inco ⁇ oration of both wild type-specific and variant allele- specific fluorescent labeled nucleosides would indicate the organism contain heterozygous alleles.
  • the present method may further be used in measuring allelic frequency by quantifying different types of fluorescent-labeled nucleosides inco ⁇ orated when the target nucleic acids are from a selected population of organisms.
  • Fluid Handling refers to those assays that are array (including microtiter-plate) based and use fluorescence, fluorescence-polarization, luminescence, radioactivity (scintillation counters), or colorimetric readouts. Fluid handling may be useful when the characterization method employs modification of the short nucleic acid fragment, e.g., when a tag or label is inco ⁇ orated into the short nucleic acid fragment.
  • These assays can be amplified by the use of enzymes such as horseradish peroxidase or alkaline phosphatase that can generate soluble or insoluble colorimetric products from soluble substrates or sensitive luminescent products.
  • Fluid Handling using microplates scales well and has been partially miniaturized by the use of 384-well plates. Fluid Handling is especially compatible with commercial robotics and readout systems such as fluorometers, and plate readers. The data is easy to archive and manipulate.
  • labeled or tagged nucleoside(s) are inco ⁇ orated onto an immobilized ODNP (t ' .e., oligonucleotide (a) in Figure 21) by filling in a 3' recessed terminus resulting from digestion with a RE (e.g., EcoN I) in a way similar to that described above in the "Fluorescence Polarization" section.
  • a RE e.g., EcoN I
  • the only difference between the two filling-in reactions is that for immobilized ODNPs, even if DNA polymerase is used for the filling-in reaction, dephosphorylation of excessive labeled dNTPs prior to the reaction is not necessary.
  • the elimination of the need for dephosphorylation is due to the fact that the excessive dNTPs may be removed by a simple wash of the array.
  • a detection device may include a microscope and a monochromatic or polychromatic light source for directing light at the substrate of the array.
  • a photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate.
  • Exemplary devices are described in U.S. Patent Nos. 6,141,096, 5,143,854, and 6,045,996. These patents are inco ⁇ orated herein by reference in their entirety.
  • fluid handling may also be useful for dete ⁇ nining whether the organism from which target nucleic acids are isolated contains homozygous wild type alleles, two or more variant alleles, or both wild type and variant alleles (i.e., heterozygous alleles).
  • the method may further be used in measuring allelic frequency by quantifying different types of labeled nucleosides inco ⁇ orated when the target nucleic acids are from a selected population of organisms.
  • the small nucleic acid fragment(s) may, optionally, undergo a step of fractionation prior to a step of detection.
  • the fractionation step may simply remove undesired impurities from the small fragment of interest, to allow more convenient and/or more accurate characterization of the fragment.
  • This type of fractionation step may be referred to as purification.
  • the fractionation may separate nucleic acids from one another (such as in chromatography) and the detection technique is simply determining whether the nucleic acid is, or is not, present at a particular time and space (e.g., using ultraviolet detection to determine whether a nucleic acid is eluting from a chromatography column).
  • a detection methodology may be advantageous to couple a detection methodology with one or more methodologies for the fractionation of small nucleic acid fragments.
  • such fractionation methodologies include, but are not limited to, electrophoresis including polyacrylamide or agarose gel electrophoresis and capillary electrophoresis, and liquid chromatography (LC) including high pressure liquid chromatography (HPLC) and denaturing high pressure liquid chromatography (DHPLC).
  • electrophoresis including polyacrylamide or agarose gel electrophoresis and capillary electrophoresis
  • LC liquid chromatography
  • HPLC high pressure liquid chromatography
  • DPLC denaturing high pressure liquid chromatography
  • electrophoretic refers generally to those separation techniques based on the mobility of nucleic acid in an electric field. Negatively charged nucleic acid migrates towards a positive electrode and positively charged nucleic acid migrates toward a negative electrode. Charged species have different migration rates depending on their total charge, size, and shape, and can therefore be separated.
  • An electrophoresis apparatus consists of a high-voltage power supply, electrodes, buffer, and a support for the buffer such as a polyacrylamide gel, or a capillary tube.
  • a support for the buffer such as a polyacrylamide gel, or a capillary tube.
  • Open capillary tubes are used for many types of samples and the other gel supports are usually used for biological samples such as protein mixtures or nucleic acid fragments.
  • the most powerful separation method for nucleic acid fragments is PAGE, generally in a slab gel format.
  • the major limitation of the current technology is the relatively long time required in performing the gel electrophoresis of nucleic acid fragments produced in sequence reactions. An increased magnitude (10-fold) can be achieved with the use of capillary electrophoresis which utilize ultrathin gels.
  • CE Capillary electrophoresis in its various forms, including free solution, isotachophoresis, isoelectric focusing, PAGE, and micellar electrokinetic "chromatography,” is a suitable technology for the rapid, high resolution separation of very small sample volumes of complex mixtures.
  • CE-MS mass spectrometry
  • CE may be employed in conjunction with electrospray ionization (ESI) flow rates.
  • ESI electrospray ionization
  • Polyacrylamide gels such as those discussed above, may be applied to CE methodologies. Remarkable plate numbers per meter have been achieved with cross-linked polyacrylamide. (See, e.g., Cohen et al., Proc. Natl. Acad. Sci., USA 85:9660 (1988) reporting 10 +7 plates per meter).
  • Such CE columns as described can be employed for nucleic acid (particularly DNA) sequencing.
  • the CE methodology is in principle 25 times faster than slab gel electrophoresis in a standard sequencer. For example, about 300 bases can be read per hour.
  • the separation speed is limited in slab gel electrophoresis by the magnitude of the electric field that can be applied to the gel without excessive heat production. Therefore, the greater speed of CE is achieved through the use of higher field strengths (300 N/cm in CE versus 10 N/cm in slab gel electrophoresis).
  • the capillary format reduces the amperage and thus power and the resultant heat generation.
  • multiple capillaries may be used in parallel to increase throughput and may be used in conjunction with high throughput sequencing.
  • the major disadvantage of capillary electrophoresis is the limited volume of sample that can be loaded onto the capillary. This limitation may be circumvented by concentrating large sample volumes prior to loading the capillary with the accompanying benefit of > 10-fold enhancement in detection.
  • the most popular method of preconcentration in CE is sample stacking.
  • Sample stacking depends on the matrix difference (i.e., pH and ionic strength) between the sample buffer and the capillary buffer, so that the electric field across the sample zone is more than in the capillary region.
  • a large volume of sample in a low concentration buffer is introduced for preconcentration at the head of the capillary column.
  • the capillary is filled with a buffer of the same composition, but at higher concentration.
  • Sample ions reach the capillary buffer and the lower electric field, they stack into a concentrated zone.
  • Sample stacking has increased detectability by 1-3 orders of magnitude.
  • preconcentration may be achieved by applying isotachophoresis (ITP) prior to the free zone CE separation of analytes.
  • ITP is an electrophoretic technique that allows microliter volumes of sample to be loaded onto the capillary, in contrast to the low nL injection volumes typically associated with CE. This technique relies on inserting the sample between two buffers (leading and trailing electrolytes) of higher and lower mobility followed by the analyte.
  • the technique is inherently a concentration technique, where the analytes concentrate into pure zones migrating with the same speed.
  • the technique is currently less popular than the stacking methods described above because of the need for several choices of leading and trailing electrolytes, and the ability to separate only cationic or anionic species during a separation process.
  • nucleic acid sequencing process Central to the nucleic acid sequencing process is the remarkably selective electrophoretic separation that may be achieved with nucleic acid and/or OD ⁇ fragments. Separations are routinely achieved with fragments differing in sequence by only a single nucleotide. This methodology is suitable for separations of fragments up to 1000 bp in length.
  • a further advantage of sequencing with cleavable tags is that there is no requirement to use a slab gel fo ⁇ nat when nucleic acid fragments are separated by PAGE. Since numerousx samples are combined (4 to 2000) there is no need to run samples in parallel as is the case with current dye-primer or dye-terminator methods (i.e., ABI 373 sequencer). Since there is no reason to run parallel lanes, there is no reason to use a slab gel.
  • a tube gel format for the electrophoretic separation method. It has been shown that considerable advantage is gained when a tube gel format is used in place of a slab gel format. (Grossman et al., Ce/2et. Anal Tech. Appl. 9:9 (1992)). This is due to the greater ability to dissipate Joule heat in a tube format compared to a slab gel which results in faster ran times (by 50%), and much higher resolution of high molecular weight nucleic acid fragments (greater than 1000 nt). Long reads are critical in genomic sequencing. Therefore, the use of cleavable tags in sequencing has the additional advantage of allowing the user to employ the most efficient and sensitive nucleic acid separation method that also possesses the highest resolution.
  • CE is a powerful method for nucleic acid sequencing, particularly DNA sequencing, forensic analysis, PCR product analysis and restriction fragment sizing.
  • CE is faster than traditional slab PAGE since with capillary gels a higher 6+potential field can be applied, but has the drawback of allowing only one sample to be processed per gel.
  • micro- fabricated devices MFDs are employed to combine the faster separations times of CE with the ability to analyze multiple samples in parallel.
  • MFDs permit an increase in information density in electrophoresis by miniaturizing the lane dimension to about 100 micrometers.
  • the current density of capillary arrays is limited to the outside diameter of the capillary tube. Microfabrication of channels produces a higher density of arrays.
  • Microfabrication also permits physical assemblies not possible with glass fibers and links the channels directly to other devices on a chip.
  • a gas chromatograph and a liquid chromatograph have been fabricated on silicon chips, but these devices have not been widely used.
  • Several groups have reported separating fluorescent dyes and amino acids on MFDs. (Manz et al., J. Chromatography 593:253 (1992); Effenhauser et al., Anal Chem. 65:2637 (1993)). Photolithography and chemical etching can be used to make large numbers of separation channels on glass substrates.
  • HEC hydroxyethyl cellulose
  • Liquid chromatography including HPLC and DHPLC, may be used in conjunction with one of the detection methodologies discussed above such as, for example, fluorescence polarization, mass spectrometry and/or electron ionization.
  • LC, HPLC and/or DHPLC may be utilized in conjunction with a UN detection methodology.
  • a fractionation step provides the separation of complex mixtures of non-volatile compounds prior to detection.
  • LC may be used for compounds that have a high molecular weight or are too sensitive to heat to be analyzed by GC.
  • the most common ionization methods that are interfaced to LC are ESI and Atmospheric Chemical Ionization (APCI) in positive and negative-ion modes.
  • the LC is done in most cases by RP-HPLC, and the buffer system should not contain involatile salts (e.g., phosphates).
  • ESI can be used for m/z 500-4000 and is done at low resolving power.
  • LC-MS can be used to look at a wide variety of biologically important compounds including, peptides, proteins, oligonucleotides, and lipids.
  • the chromatography for gene expression profiling or genotyping by LC/MS can be performed using a ProStar Helix System (catalog # HelixsysOl) which is composed of two pumps, a column oven, a UV detector, a degasser, a mixer and an autoinjector.
  • the column is like a Varian Microsorb MV (catalog number R0086203F5), C18 packing with 5 uM particle size, with 300 Angstroms pore size, 4.6 mm x 50 mm.
  • the column can be run at 30°C to 40°C with a gradient of acetonitrile in 100 mM Triethylamine acetate (TEAA) and 0.1 mM EDTA.
  • the following HPLC method can be used to separation the fragments on the column: Buffer A is 100 mM TEAA with 0.1 mM EDTA, Buffer B is 100 mM TEAA with 0.1 mM EDTA and 25% (V/V) acetonitrile, 0-3 minutes there is a gradient of 20%> B to 25%) B, at 3.01 minutes to 4 minutes, there is a ramp to 45%> B, at 4.01 to 4.5 minutes there is a ramp to 95%> B, at 4.51 minutes there is 1 minutes hold at 20%) B to re-equilibrate the column.
  • the column can be run at 30-50C by adjusting the column oven to 30C to 50C.
  • the flow rate can be 0.5 to 1.5 ml per minute.
  • HPLC High-Performance Liquid Chromatography
  • HPLC instruments consist of a reservoir of mobile phase, a pump, an injector, a separation column, and a detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase.
  • the pumps provide a steady high performance with no pulsating, and can be programmed to vary the composition of the solvent during the course of the separation.
  • Exemplary detectors useful within the methods of present invention include UV-VIS abso ⁇ tion, or fluorescence after excitation with a suitable wavelength, mass spectrometers and IR spectrometers.
  • Oligonucleotides labeled with fluorochromes may replace radio-labeled oligonucleotides in semi-automated sequence analysis, minisequencing and genotyping. (Smith et al., Nature 321:674 (1986)).
  • IP-RO-HPLC on non-porous PS/DVB particles with chemically bonded alkyl chains may be employed in the analysis of both single and double-strand nucleic acids. (Huber et al., Anal. Biochem.
  • IP-RP-HPLC enables a strictly size-dependent separation.
  • Denaturing HPLC is an ion-pair reversed-phase high performance liquid chromatography methodology (IP-RP-HPLC) that uses a non- porous C-18 column as the stationary phase.
  • the column is comprised of a polystyrene-divinylbenzene copolymer.
  • the mobile phase is comprised of an ion- pairing agent of triethylammonium acetate (TEAA), which mediates binding of DNA to the stationary phase, and acetonitrile (ACN) as an organic agent to achieve subsequent separation of the DNA from the column.
  • TEAA triethylammonium acetate
  • ACN acetonitrile
  • a linear gradient of acetonitrile allows separation DHPLC identifies mutations and polymo ⁇ hisms based on detection of heteroduplex formation between mismatched nucleotides in double stranded PCR amplified DNA. Sequence variation creates a mixed population of heteroduplexes and homoduplexes during reannealling of wild type and mutant DNA of fragments based on size and/or presence of heteroduplexes (this is the traditional use of the DHPLC technology). When this mixed population is analyzed by HPLC under partially denaturing temperatures, the heteroduplexes elute from the column earlier than the homoduplexes because of their reduced melting temperature. Analysis can be performed on individual samples to determine heterozygosity, or on mixed samples to identify sequence variation between individuals.
  • the DHPLC column in a non-denaturing mode in order to separate identically sized DNA fragments which possess a different nucleotide composition.
  • the non-denaturing mode may be applicable where, for example, a 6-mer contains a C - T single nucleotide polymo ⁇ hism (SNP) such as where the wild-type single strand DNA fragment has the nucleotide sequence 5'-AACCCC-3' and where the mutant single strand DNA fragment has the nucleotide sequence 5'-AATCCC-3'.
  • SNP single nucleotide polymo ⁇ hism
  • Fragments as short as 1-mers, 2-, 3-, 4-, 5- , 6-, 7-, 8-, to 16-mers show different mobilities (retention times) on the DHPLC instmment.
  • HPLC as both sizing and DHPLC applications work on a wide pore silica based material. Porous materials have the advantage of high sample capacity for semipreparative work. This is marketed by HP as Eclipse dsDNA columns.
  • Detection methodologies employed in the methods of the present invention may optionally employ one or more computer algorithms for analyzing the derived sequence information.
  • Algorithms of the present invention may be encompassed within software packages that convert a detection signal, such as a mass- to-charge ratio of a given small nucleic acid fragment, to a genotyping call.
  • Exemplary software packages may comprise the following: a peak identification algorithm which identifies peaks above a certain threshold of intensity (area under the curve), an algorithm that identifies and records the mass to charge ratio of the peaks between the scan intervals, an algorithm that calculates the intensity of peaks by measuring the area under the curve, an algorithm that calculates the number of peaks during a scan interval, an algorithm that calculates the ratio of each set of two peaks, an algorithm that calculates the allele calling from the ratiometric values.
  • the software package and algorithms may record the sample identification (sample ID), source, primer name and sequence, mass to charge ratio of expected fragment, estimation of expected mass to charge ratio, mass spectrometry details, sample plate ID, sample well ID, date and time, number of peaks observed, observed mass to charge ratio, and calculated allele call.
  • the algorithms may also download the data to existed databases and check for accuracy of recording.
  • a complete genotyping system for use with a mass spectrometry detection system can be composed of the following: A computer (e.g., a Dell Optiplex Gx 110, with a CD-ROM), a software package to control the mass spectrometry, a thermocycler, and a robot that moves microtiter plates on and off the autoinjector, a simple HPLC to desalt the PCR or amplification reaction, the mass spectrometer such as an Agilent LC-quadrapole, ES-TOF, a Micromass ES-TOF or APCI-quadrupole, and a software program to call the alleles.
  • a computer e.g., a Dell Optiplex Gx 110, with a CD-ROM
  • a software package to control the mass spectrometry e.g., a thermocycler, and a robot that moves microtiter plates on and off the autoinjector
  • a simple HPLC to desalt the PCR or amplification reaction e.g
  • a complete genotyping system for use with a fluorescence based detection system can be composed of the following: a peak identification algorithm which identifies peaks above a certain threshold of intensity (area under the curve), an algorithm that identifies and records the retention time of the peaks between certain time intervals (i.e., between 1.75 and 3 minutes in a 5 minute run), an algorithm that calculates the intensity of peaks by measuring the area under the curve, an algorithm that calculates the number of peaks between a certain time interval (i.e., between 1.75 and 3 minutes in a 5 minute run), an algorithm that calculates the ratio of each set of two peaks, an algorithm that calculates the allele calling from the ratiometric values.
  • the software package and algorithms record the sample identification (sample ID), source, primer name and sequence, length of expected fragment, estimation of expected retention time, chromatography details, sample plate ID, sample well ID, date and time, number of peaks observed, observed retention times, and calculated allele call.
  • the algorithms will also download the data to existed databases and check for accuracy of recording.
  • the software package that converts the presence of a label on the fragment to a genotyping call is composed of the following: an algorithm that calculates the allele calling from the ratiometric values of fluorescence or fluorescence polarization.
  • the software package and algorithms record the sample identification (sample ID), source, primer name and sequence, mass to charge ratio of expected fragment, estimation of expected fluorescence ratios, instrument details, sample plate ID, sample well ID, date and time, and calculated allele call.
  • the algorithms will also download the data to existing databases and check for accuracy of recording.
  • the software package that converts the mass to charge ratio of the fragment to a genotyping call is composed of the following: an algorithm that records the temporal parameter of the chromatography, a peak identification algorithm which identifies peaks above a certain threshold of intensity (area under the curve), an algorithm that identifies and records the mass to charge ratio of the peaks between the scan intervals, an algorithm that calculates the intensity of peaks by measuring the area under the curve, an algorithm that calculates the number of peaks during a scan interval, an algorithm that calculates the ratio of each set of two peaks, an algorithm that calculates the allele calling from the ratiometric values.
  • the software package and algorithms record the sample identification (sample ID), source, primer name and sequence, mass to charge ratio of expected fragment, estimation of expected mass to charge ratio, chromatography details, elution time of each fragments, mass spectrometry details, sample plate ID, sample well ID, date and time, number of peaks observed, observed mass to charge ratio, and calculated allele, sequence identity, or gene identity call.
  • the algorithms will also download the data to existed databases and check for accuracy of recording.
  • the present invention provides methodology for the detection of mutations at defined nucleotide loci within target nucleic acids and/or measurement of genetic variations in parallel. Also provided herein, are various "readout" technologies that may be employed with the methodologies of the present invention for detecting, for example, the size and/or molecular weight of one or more single-strand fragment comprising the mutations and/or genetic variations. Methods according to the present invention will find utility in a wide variety applications wherein it is necessary to identify such a mutation at a defined nucleotide locus or measure genetic variations.
  • Such applications include, but are not limited to, genetic analysis for hereditary diseases, tumor diagnosis, disease predisposition, forensics or paternity, crop cultivation and animal breeding, expression profiling of cell function and/or disease marker genes, and identification and/or characterization of infectious organisms that cause infectious diseases in plants or animals and/or that are related to food safety.
  • the present methods may be utilized to greatly increase the specificity, sensitivity and throughput of the assay while lowering costs in comparison to conventional methods currently available in the art. Described below are certain exemplary applications of the present invention.
  • mRNAs are transcribed from single copy sequences.
  • Another property of cDNAs is that they represent a longer region of the genome because of the introns present in the chromosomal version of most genes. The representation varies from one gene to another but can be very significant as many genes cover more than 100 kb in genomic DNA, represented in a single cDNA.
  • molecular profiling is the use of probes from one species to find clones made from another species. Sequence divergence between the mRNAs of mouse and man permits specific cross-reassociation of long sequences, but except for the most highly conserved regions, prevents cross-hybridization of PCR primers.
  • PCR-based (Lambolez et al., Neuron 9:241, 1992) and cRNA-based (Van Gelder et al., Proc. Natl. Acad. Sci. USA 57:1663, 1990) probes from single cells. After electrical recordings, the cytoplasmic contents of a single cell were aspirated with patch-clamp microelecfrodes for in situ cDNA synthesis and amplification. PCR was used to amplify cDNA of selective glutamate receptor mRNAs from single Purkinje cells and GFAP mRNA from single glia in organotypic cerebellar culture (Lambolez et al., Neuron 9:247, 1992).
  • transcription promoter sequences were designed into primers for cDNA synthesis and complex antisense cRNAs were generated by in vitro transcription with bacteriophage RNA polymerases.
  • the array of the present invention is useful for determining whether a particular cDNA molecule is present in cDNAs from a biological sample and further determine whether genetic variation(s) exist in the cDNA molecule.
  • DNA sequence variation offers a number of practical advantages over such conventional criteria as f ⁇ nge ⁇ rints, blood type, or physical characteristics.
  • DNA analysis readily permits the deduction of relatedness between individuals such as is required in paternity testing.
  • Genetic analysis has proven highly useful in bone marrow transplantation, where it is necessary to distinguish between closely related donor and recipient cells.
  • Two types of probes are now in use for DNA finge ⁇ rinting by DNA blots.
  • Polymo ⁇ hic minisatellite DNA probes identify multiple DNA sequences, each present in variable forms in different individuals, thus generating patterns that are complex and highly variable between individuals.
  • VNTR probes identify single sequences in the genome, but these sequences may be present in up to 30 different forms in the human population as distinguished by the size of the identified fragments.
  • the probability that unrelated individuals will have identical hybridization patterns for multiple VNTR or minisatellite probes is very low. Much less tissue than that required for DNA blots, even single hairs, provides sufficient DNA for a PCR-based analysis of genetic markers. Also, partially degraded tissue may be used for analysis since only small DNA fragments are needed.
  • the methods of the present invention are useful in characterizing polymo ⁇ hism of sample DNAs, therefore useful in forensic DNA analyses. For example, the analysis of 22 separate gene sequences in a sample, each one present in two different forms in the population, could generate 1010 different outcomes, permitting the unique identification of human individuals.
  • Viral oncogenes are transmitted by retrovirases while their cellular counte ⁇ arts (c-oncogenes) are already present in normal cells.
  • the cellular oncogenes can, however, be activated by specific modifications such as point mutations (as in the c-K-ras oncogene in bladder carcinoma and in colorectal tumors), small deletions and small insertions.
  • point mutations as in the c-K-ras oncogene in bladder carcinoma and in colorectal tumors
  • small deletions small insertions.
  • point mutations, small deletions or insertions may also inactivate the so-called “recessive oncogenes” and thereby leads to the formation of a tumor (as in the retinoblastoma (Rb) gene and the osteosarcoma).
  • the present invention is useful in detecting or identifying the point mutations, small deletions and small mutations that activate oncogenes or inactivate recessive oncogenes, which in turn, cause cancers.
  • HLA histocompatibility antigens
  • the T-cells expressing a specific T-cell receptor which fits to the foreign antigen could therefore be eliminated from the T-cell pool.
  • Such analyses are possible by the identification of antigen-specific variable DNA sequences which are amplified by PCR and hence selectively increased.
  • the specific amplification reaction permits the single cell-specific identification of a specific T-cell receptor.
  • the present invention is useful for determining gene variations in T-cell receptor genes encoding variable, antigen-specific regions that are involved in the recognition of various foreign antigens.
  • Hereditary diseases have long since been diagnosed by phenotypic analyses (anamneses, e.g., deficiency of blood: thalassemias), chromosome analyses (karyotype, e.g., mongolism: trisomy 21) or gene product analyses (modified proteins, e.g., phenylketonuria: deficiency of the phenylalanine hydroxylase enzyme resulting in enhanced levels of phenylpyravic acid).
  • phenotypic analyses anamneses, e.g., deficiency of blood: thalassemias
  • chromosome analyses karyotype, e.g., mongolism: trisomy 21
  • gene product analyses modified proteins, e.g., phenylketonuria: deficiency of the phenylalanine hydroxylase enzyme resulting in enhanced levels of phenylpyravic acid.
  • the additional use of nucleic acid detection methods considerably increases the range
  • the modification of just one of the two alleles is sufficient for disease (dominantly transmitted monogenic defects); in many cases, both alleles must be modified (recessively transmitted monogenic defects).
  • the outbreak of the disease is not only dete ⁇ nined by the gene modification but also by factors such as eating habits (in the case of diabetes or arteriosclerosis) or the lifestyle (in the case of cancer). Very frequently, these diseases occur in advanced age. Diseases such as schizophrenia, manic depression or epilepsy should also be mentioned in this context; it is under investigation if the outbreak of the disease in these cases is dependent upon environmental factors as well as on the modification of several genes in different chromosome locations.
  • bladder carcinoma bladder carcinoma, colorectal tumors, sickle-cell anemia, thalassemias, al-antitrypsin deficiency, Lesch-Nyhan syndrome, cystic fibrosis/mucoviscidosis, Duchenne/Becker muscular dystrophy, Alzheimer's disease, X- chromosome-dependent mental deficiency, and Huntington's chorea, phenylketonuria, galactosemia, Wilson's disease, hemochromatosis, severe combined immunodeficiency, alpha- 1-antitrypsin deficiency, albinism, alkaptonuria, lysosomal storage diseases, Ehlers-Danlos syndrome, hemophilia, glucose-6-phosphate dehydrogenase disorder, agammaglobulimenia, diabetes insipidus, Wiskott-Aldrich syndrome, Fabry's disease, fragile X-synd
  • the present invention is useful to detect and/or measure genetic variations that are involved in infectious diseases, especially those in drag resistance genes.
  • the present invention facilitates the characterization and classification of organisms that cause infectious diseases and consequently the treatment of such diseases caused by these organisms.
  • This example discloses the use of Electrospray-Liquid- Chromatography/Mass Mpectrometry (ES-LC/MS) for determining the molecular weight of single-strand oligonucleotide (ODN) fragments of 4, 6, 8 and 10 nucleotides in length (Table 4).
  • ES-LC/MS Electrospray-Liquid- Chromatography/Mass Mpectrometry
  • ODNs were synthesized by Midland Certified reagents of Midland TX. The ODNs were diluted to a concentration of 0.5 nm/ul in 0.01 M Tris-HCl, 0.1 mM EDTA to create a stock solution. Each stock solution of ODN was subsequently diluted 1 :10, 1:100 and 1 : 1000 in purified water.
  • the chromatography was perfom ed using tlie following system: a ProStar Helix System (catalog # HelixsysOl) wliich is composed of two pumps, a column oven, a UV detector, a degasser, a mixer and an autoinjector.
  • the column is a Varian Microsorb MV (catalog number R0086203F5), C18 packing with 5 uM particle size, with 300 Angstroms pore size, 4.6 mm x 50 mm.
  • the column was ran at 30°C to 40°C with a gradient of acetonitrile in 100 mM Triethylamine acetate (TEAA) and 0.1 mM EDTA.
  • Buffer A is 100 mM TEAA with 0.1 mM EDTA
  • Buffer B is 100 mM TEAA with 0.1 mM EDTA and 25% (V/V) acetonitrile
  • the column was run at 40°C by adjusting the column oven to 40°C.
  • the flow rate was 1.5 ml per minute. About 200 nanogram of fragment was injected per 10 microliter volume.
  • the UV detector measures the effluent of the column. Table 4
  • the mass spectra looks similar to the 1/10 dilution, with peaks of expected molecular weight 1181.4 and 590.2.
  • the peak at 1203.5 is the Na+ adduct (+23 Daltons) of the 4-mer.
  • the peaks at 621.2, 659.2, 868.3, 948.3 are either fragmentation products or background ( Figure 2).
  • the 906.7 mass represents an m/z value of 0.5 that of the singly charged species (i.e., the 906.7 species has two charges.).
  • an n+0.5 and n+1 charge is seen at 907.3 and 907.8. This is typical with electrospray ionization with polymeric molecules.
  • Figure 4B the mass spectrum shows peaks of expected molecular weight 1815.6.
  • the peak at 1837.5 is the Na+ adduct (+23 Daltons) of the 6- mer.
  • Figure 5 shows the chromatogram of the 1/100 dilution of the 6 mer with the 906.8 peak normalized to 100%.
  • the dilution at 1/1000 is shown which is about at the lower limit of detection for the ES-TOF.
  • the peak at 906.8 is clearly visible above the background. More "background" is visible in the spectra as the lower limits of detection are being pushed.
  • Figure 9B shows the mass spectra with peaks of expected molecular weight 2996. The peak at 3017.9 is the Na+ adduct (+23 Daltons) of the 10-mer.
  • Figure 10 shows the 1/100 dilution of the 10- mer with the 1497J peak normalized to 100%>. In Fieure 11. the dilution at 1/1000 is
  • This example discloses a methodology for determining the presence of a single nucleotide polymo ⁇ hism (SNP) at a defined location within a target nucleic acid by measuring the molecular weight of a single-strand nucleic acid fragment released after digestion of an amplicon with a restriction endonuclease.
  • SNP single nucleotide polymo ⁇ hism
  • two SNPs are discriminated using the generation of a small fragment by Fok I digestion which is then measured using mass spectrometry (ES-TOF).
  • the forward and reverse primers each contain a Fok I recognition sequence.
  • the primers are used to amplify an allele of interest from the lambda genome.
  • the Fok I cutting sites are designed such that after the restriction digest is performed, a fragment of 6 or 10 nucleotides is formed, depending on the primer set used.
  • An amplicon was generated by PCR amplifying the genomic DNA of
  • SEQ ID NO: 13 (Table 6) using the first ODNP and second ODNP of primer set 1 (Table 5, i.e., SEQ ID NOs: 9 and 10, respectively).
  • This amplicon was digested with Fok I to release a 10-mer single-stranded nucleic acid fragment comprising the sequence 5'-ATTATTCAGC-3' (SEQ ID NO: 15).
  • An amplicon was generated by PCR amplifying the genomic DNA of
  • SEQ ID NO: 14 (Table 6) using the first ODNP and second ODNP of primer set 2 (Table 5, i.e., SEQ ID NOs: 11 and 12, respectively). This amplicon was digested with Fok I to release a 6-mer single-stranded nucleic acid fragment comprising the sequence 5'-TTATTA-3'.
  • the 100 ⁇ l PCR reactions comprised 100 ng genomic DNA; 0.5 ⁇ M of each first ODNP and second ODNP; 10 mM Tris, pH 8.3; 50 mM KC1; 1.5 mM MgCl 2; 200 ⁇ M each dNTP; 4 units TaqTM DNA Polymerase (Boehringer Mannheim; Indianapolis, IN), and 880 ng TaqStartTM Antibody (Clontech, Palo Alto, CA).
  • Thermocycling conditions were as follows: 94°C for 5 minutes initial denaturation; 45 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; final extension at 72°C for 5 minutes.
  • An MJ Research 9600 thermocycler (MJ Research, Watertown, MA) was used for all PCR reactions. Products were visualized via a 2.0% agarose gel stained with ethidium bromide.
  • ES-LC/MS electrospray-liquid-chromatography/mass spectrometry, time-of flight (TOF)
  • TOF time-of flight
  • This example describes the separation and identification of short genotyping DNA fragments by liquid chromatography.
  • the identification of the DNA fragments is by UV absorbance and retention time on the column.
  • the chromatography system is from Varian (Walnut Creek, CA) and is a ProStar Helix System (catalog # HelixsysOl) which is composed of two pumps, a column oven, a UV detector, a degasser, a mixer and an autoinjector.
  • the column is a Varian Microsorb MV (catalog number R0086203F5), C18 packing with 5 uM particle size, with 300 Angstroms pore size, 4.6 mm x 50 mm.
  • the column was run at 30°C to 40°C with a gradient of acetonitrile in 100 mM Triethylamine acetate (TEAA) and 0.1 mM EDTA. The type of gradient is described in the text.
  • 10-merC 5'-GAACATCCAT -3' (SEQ ID NO. 8)
  • the polymo ⁇ hisms in the 8-mers and 10-mers are underlined.
  • the 8- mers B and C differ from 8-mer A by only a single base.
  • the 10-mers B and C differ from 10-mer A by only a single base.
  • Buffer A is 100 mM TEAA with 0.1 mM EDTA
  • Buffer B is 100 mM TEAA with 0.1 mM EDTA and 25% (VN) acetonitrile
  • the column was ran at 40°C by adjusting the column oven to 40°C.
  • the flow rate was 1.5 ml per minute.
  • the injection volume was 10 microliters and 200 nanogram of fragment was injected per 10 microliter volume. Different combinations of the 4-mer, 6-mer, 8-mer and 10-mer were injected to determine the chromagraphic behavior.
  • Trace 4 shows a single peak of 8-merA and Trace 6 shows a single Trace of 8-merB. Genotypes can be directly inferred from the retention times during the chromatography, even from fragments that differ by only a single base.
  • Figure 14 shows an 8-mer genotyping result and a 10-mer genotyping result. In panel A, the "T" allele is position 2 is discriminated from the "C” allele in position 2 and the "C” allele in position 5 from the "T” allele in position 5.
  • the following example describes the amplification of a specific sequence from the lambda genome in which the primers contain the Fok I recognition sequence (both the forward and reverse primers).
  • the resulting amplicon contains a
  • Double-Fok I cutting site which liberates a small oligonucleotide fragment, which is then subjected to a chromatography step and identified by UV absorbance.
  • Two sets of primers were designed to generate two different amplicons from two different regions of the lambda genome.
  • RE5P01F 5'- GAAGTGATGGGGATGCGGAAAGAG-3' (SEQ ID NO. 9)
  • RE5P02R 5'- GTAAGCCACAGGATGAGGAACGGG-3' (SEQ ID NO. 18)
  • RE5P03F 5'-AAAGCTGGCAGGATGACCGGCAGA -3' (SEQ ID NO. 11)
  • RE5P04R 5'-AGCGTCTGTTGGATGTCGTGGCGG -3' (SEQ ID NO. 19)
  • RE5P01F and RE5P02R are primer set one and RE5P03F and
  • RE5P04R are primer set 2. All oligonucleotides were synthesized by Midland Reagent
  • the 25 ⁇ l PCR reactions were composed of 25 ng genomic DNA, 0.5 ⁇ M forward and reverse primers, 10 mM Tris pH 8.3, 50 mM KC1, 1.5 mM MgCl 2 , 200 ⁇ M each dNTP, 4 Units Taq DNA Polymerase (Boehringer Mannheim, Indianapolis, IN), and 880 ng TaqStart Antibody (Clontech, Palo Alto, CA).
  • Thermocy cling conditions were as follows: 94°C for 5 minutes initial denaturation; 45 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; final extension at 72°C for 5 minutes.
  • a MJ Research 9600 thermocycler (MJ Research, Watertown, MA) was used for all PCR reactions.
  • Buffer A is 100 mM TEAA with 0.1 mM EDTA
  • Buffer B is 100 mM TEAA with 0.1 mM EDTA and 25% (V/V) acetonitrile
  • the column was run at 40°C by adjusting the column oven to 40°C.
  • the flow rate was 1.5 ml per minute.
  • the injection volume was 10 to 30 microliters.
  • the controls for the chromatograms are shown.
  • the no-template control is shown in which the uninco ⁇ orated primers (primer set 1) can be seen eluting after the 4 minute mark.
  • the no-template control is shown in which the uninco ⁇ orated primers (primer set 2) can be seen eluting after the 4 minute mark.
  • the +template control is seen prior to cutting with Fok I.
  • the large amplicon is seen eluting at 4.6 minutes.
  • a peak is seen at 1.24 minutes which is due to the Fok I enzyme of buffer (the no-template control was mixed with the Fok I buffer components as a control).
  • the large peak at 0.5 to 1 minute is due to the PCR components.
  • This example discloses the use of fluorescence polarization (FP) and the EcoN I template-directed primer extension (fill-in) assay in assigning genotype.
  • Oligonucleotides used are listed in Table 7. Four synthetic 48-mers with identical sequence except for position 23 were prepared (CF508-48), the variant bases are shown as boldface letters. PCR and EcoN I primers and synthetic template oligonucleotides were obtained from Life Technologies (Grand Island, NY).
  • BFL, and BTR were obtained from NEN Life Science Products, Inc. (Boston, MA). Unlabeled ddNTPs were purchased from Pharmacia Biotech (Piscataway, NJ).
  • Fluorescence polarization value was calculated using the formula:
  • Tvv is the emission intensity measured when the excitation and emission polarizers are parallel and Ivh is the emission intensity measured when the emission and excitation polarizers are oriented pe ⁇ endicular to each other.
  • the degree of polarization is expressed by the unit mP, or a 0.001 ratio between (Iw — Ivh) and (I + Ivh).
  • the average FP value and standard deviation of the negative control samples were determined for each set of experiment. The FP value of the test sample reactions was then compared to the average FP value of the control samples. If the net change is >40 mP (more than seven times the standard deviation of the controls), the test sample is scored as positive for the allele.
  • Synthetic template sequences (bold) are bases to be tested.
  • FAM-ddA a FAM-ddC (mP) a FAM-ddG (mP) a FAM-ddU (mP) a
  • nucleoside complementary to the polymo ⁇ hic base was inco ⁇ orated and showed significant FP change, with net gains of FP of at least 50 mP, which is nine times standard deviation of the controls.
  • BFL-ddA BODIPY-fluorscein-ddA
  • TMR-ddC N ⁇ N ⁇ N'-tetramethyl- ⁇ -carboxyrhodamine
  • ROX-ddg BODIPY-Texas Red-ddU
  • Marker D18S8 and the C282Y mutation in the human hereditary hemochromatosis (HFE) gene implicated in hemochromatosis were used in FP-TDI assays designed to test for both alleles in the same reaction.
  • HFE human hereditary hemochromatosis
  • genomic DNA samples from 34 individuals were amplified and then cut with EcoN I and the 3 '-ends filled in, in the presence of BFL-ddA and ROX-ddG.
  • the FP values of the reaction mixtures were read at the BFL and ROX emission wavelengths, respectively, and the results are plotted and shown in Figure 18 as changes in fluorescence polarization.
  • the results are plotted in mP units above the average polarization of the negative controls.
  • a change of 40 mP for a dye-terminator is scored as positive.
  • DNA samples from 34 individuals and 6 water blanks were used.
  • O samples with failed PCR amplification.
  • the FP values cluster into four groups. In the upper left corner of the plot, the samples have high FP for ROX-ddG but low FP for BFL-ddA, signifying that they are of homozygous G genotype ( ⁇ ).
  • the heterozygous A/G samples ( ⁇ ) exhibit high FP values in both BFL-ddA and ROX-ddG and occupy the right upper comer of the plot.
  • the homozygous A/A samples ( ) are found in the lower right comer, with low ROX- ddG but high BFL-ddA FP values.
  • the negative controls (•) and samples with failed PCR reactions (o) occupy the area near the origin with low FP values for both dyes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

La présente invention concerne la détermination de l'identité d'un nucléotide à étudier dans une molécule d'acide nucléique cible par combinaison de la cible avec deux amorces. On immobilise la première amorce sur un substrat, et elle s'hybride avec et se développe depuis un emplacement 3' du nucléotide à étudier dans la cible, de façon à incorporer le complément du nucléotide à étudier dans un premier produit d'extension. La seconde amorce s'hybride alors avec et se développe sur la base du premier produit d'extension, qui est immobilisé sur le substrat via la première amorce, en un emplacement 3' du complément du nucléotide à étudier, de façon à incorporer le nucléotide à étudier dans un second produit d'extension. Le second produit d'extension se dissocie alors du premier produit d'extension, et donc du substrat, et se ré-hybride avec une autre molécule d'amorce qui ne s'est pas développée. La première amorce non développée se développe alors depuis un emplacement 3' du nucléotide à étudier dans le second produit d'extension, de façon à former, par combinaison avec le second produit d'extension, un fragment d'acide nucléique à double brin. Les deux amorces sont conçues pour incorporer une partie de la séquence de reconnaissance d'une endonucléase de restriction (RE) qui reconnaît une séquence nucléotide partiellement variable interrompue, en l'occurrence une séquence sous la forme D-N-S où D et S désignent des séquences de nucléotides spécifiques essentielles pour la reconnaissance de la RE, et N est une séquence constituée de n nucléotides viables également nécessaires à la reconnaissance de la RE. La première amorce incorpore la séquence D, la seconde amorce incorpore la séquence S, et elles sont conçues, dans la perspective de la cible, de façon à produire un fragment d'acide nucléique où les séquences constantes D et S sont séparées par la séquence variable N, où le nucléotide à étudier se trouve dans la région N. L'action de la RE sur le fragment d'acide nucléique fournit un petit fragment d'acide nucléique qui se prête à la caractérisation, de façon à révéler l'identité du nucléotide à étudier.
PCT/US2001/042432 2000-10-02 2001-10-01 Procédé pour le mesurage parallèle des variations génétiques WO2002029006A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU1183902A AU1183902A (en) 2000-10-02 2001-09-28 Methods for parallel measurement of genetic variations
US10/398,006 US20040019005A1 (en) 2001-10-01 2001-10-01 Methods for parallel measurement of genetic variations

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US23740900P 2000-10-02 2000-10-02
US60/237,409 2000-10-02
US24717300P 2000-11-10 2000-11-10
US24716600P 2000-11-10 2000-11-10
US24717200P 2000-11-10 2000-11-10
US24727500P 2000-11-10 2000-11-10
US24716700P 2000-11-10 2000-11-10
US60/247,166 2000-11-10
US60/247,173 2000-11-10
US60/247,167 2000-11-10
US60/247,275 2000-11-10
US60/247,172 2000-11-10
US26397101P 2001-01-24 2001-01-24
US60/263,971 2001-01-24
US26924401P 2001-02-15 2001-02-15
US60/269,244 2001-02-15
US30035001P 2001-06-21 2001-06-21
US30031901P 2001-06-21 2001-06-21
US60/300,319 2001-06-21
US60/300,350 2001-06-21
US30139401P 2001-06-27 2001-06-27
US60/301,394 2001-06-27

Publications (2)

Publication Number Publication Date
WO2002029006A2 true WO2002029006A2 (fr) 2002-04-11
WO2002029006A3 WO2002029006A3 (fr) 2002-08-29

Family

ID=27582742

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2001/030742 WO2002046447A2 (fr) 2000-10-02 2001-10-01 Procede d'identification de nucleotides a des positions determines dans des acides nucleiques cibles
PCT/US2001/030743 WO2002040126A2 (fr) 2000-10-02 2001-10-01 Procedes d'identification de nucleotides dans des positions definies dans des acides nucleiques cibles au moyen de la polarisation de fluorescence
PCT/US2001/042432 WO2002029006A2 (fr) 2000-10-02 2001-10-01 Procédé pour le mesurage parallèle des variations génétiques
PCT/US2001/030828 WO2002028501A1 (fr) 2000-10-02 2001-10-01 Genotypage par chromatographie en phase liquide de fragments d'acides nucleiques courts

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2001/030742 WO2002046447A2 (fr) 2000-10-02 2001-10-01 Procede d'identification de nucleotides a des positions determines dans des acides nucleiques cibles
PCT/US2001/030743 WO2002040126A2 (fr) 2000-10-02 2001-10-01 Procedes d'identification de nucleotides dans des positions definies dans des acides nucleiques cibles au moyen de la polarisation de fluorescence

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030828 WO2002028501A1 (fr) 2000-10-02 2001-10-01 Genotypage par chromatographie en phase liquide de fragments d'acides nucleiques courts

Country Status (2)

Country Link
AU (4) AU3922802A (fr)
WO (4) WO2002046447A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008642A2 (fr) * 2001-07-15 2003-01-30 Keck Graduate Institute Amplification de fragments d'acide nucleique au moyen d'agents de coupure
US9499818B2 (en) 2007-10-26 2016-11-22 BioMarin Technologies, B.V. Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene
US9896687B2 (en) 2003-03-21 2018-02-20 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US10179912B2 (en) 2012-01-27 2019-01-15 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US10246707B2 (en) 2008-05-14 2019-04-02 Biomarin Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US10533171B2 (en) 2009-04-24 2020-01-14 Biomarin Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
RU2775416C1 (ru) * 2021-04-27 2022-06-30 Общество с ограниченной ответственностью "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Способ преимплантационного генетического тестирования миодистрофии Дюшенна-Беккера

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4318296B2 (ja) 2001-08-29 2009-08-19 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 標識ヌクレオシドポリホスフェート
US7052839B2 (en) * 2001-08-29 2006-05-30 Amersham Biosciences Corp Terminal-phosphate-labeled nucleotides and methods of use
US7256019B2 (en) 2001-08-29 2007-08-14 Ge Healthcare Bio-Sciences Corp. Terminal phosphate blocked nucleoside polyphosphates
US7223541B2 (en) 2001-08-29 2007-05-29 Ge Healthcare Bio-Sciences Corp. Terminal-phosphate-labeled nucleotides and methods of use
US7033762B2 (en) 2001-08-29 2006-04-25 Amersham Biosciences Corp Single nucleotide amplification and detection by polymerase
US7560254B2 (en) 2001-08-29 2009-07-14 Ge Healthcare Bio-Sciences Corp. Allele specific primer extension
GB0228614D0 (en) * 2002-12-07 2003-01-15 Fu Guoliang Oligonucleotide guided analysis of gene expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040166A (en) * 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US6103463A (en) * 1992-02-19 2000-08-15 The Public Health Research Institute Of The City Of New York, Inc. Method of sorting a mixture of nucleic acid strands on a binary array
US6110709A (en) * 1994-03-18 2000-08-29 The General Hospital Corporation Cleaved amplified modified polymorphic sequence detection methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646171A4 (fr) * 1992-05-22 1998-01-07 Us Health Expression amelioree de genes humains a resistance multimedicaments et selection amelioree de cellules ayant subi une transduction par de tels genes.
US5284758A (en) * 1992-08-14 1994-02-08 Merck & Co., Inc. Process for forming cholesterol lowering compound using pseudodiplodia sp.
JPH078289A (ja) * 1993-06-29 1995-01-13 Osaka Gas Co Ltd リボソームを用いたペプチドおよびタンパク質の合成法
US6027898A (en) * 1997-08-18 2000-02-22 Transgenomic, Inc. Chromatographic method for mutation detection using mutation site specifically acting enzymes and chemicals
US6180408B1 (en) * 1998-08-21 2001-01-30 Washington University Fluorescence polarization in nucleic acid analysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040166A (en) * 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US6103463A (en) * 1992-02-19 2000-08-15 The Public Health Research Institute Of The City Of New York, Inc. Method of sorting a mixture of nucleic acid strands on a binary array
US6110709A (en) * 1994-03-18 2000-08-29 The General Hospital Corporation Cleaved amplified modified polymorphic sequence detection methods

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008642A3 (fr) * 2001-07-15 2003-07-31 Keck Graduate Inst Amplification de fragments d'acide nucleique au moyen d'agents de coupure
WO2003008642A2 (fr) * 2001-07-15 2003-01-30 Keck Graduate Institute Amplification de fragments d'acide nucleique au moyen d'agents de coupure
US10190116B2 (en) 2003-03-21 2019-01-29 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US11208657B2 (en) 2003-03-21 2021-12-28 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US9896687B2 (en) 2003-03-21 2018-02-20 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US10544416B2 (en) 2003-03-21 2020-01-28 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US10100304B2 (en) 2003-03-21 2018-10-16 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US10113165B2 (en) 2003-03-21 2018-10-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
US9926557B2 (en) 2007-10-26 2018-03-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
US10876114B2 (en) 2007-10-26 2020-12-29 Biomarin Technologies B.V. Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
US9528109B2 (en) 2007-10-26 2016-12-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
US9499818B2 (en) 2007-10-26 2016-11-22 BioMarin Technologies, B.V. Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene
US11427820B2 (en) 2007-10-26 2022-08-30 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
US10246707B2 (en) 2008-05-14 2019-04-02 Biomarin Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US10533171B2 (en) 2009-04-24 2020-01-14 Biomarin Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
US11034956B2 (en) 2009-04-24 2021-06-15 Biomarin Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
US11634714B2 (en) 2009-04-24 2023-04-25 Biomarin Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
US10179912B2 (en) 2012-01-27 2019-01-15 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US10913946B2 (en) 2012-01-27 2021-02-09 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
RU2775416C1 (ru) * 2021-04-27 2022-06-30 Общество с ограниченной ответственностью "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Способ преимплантационного генетического тестирования миодистрофии Дюшенна-Беккера

Also Published As

Publication number Publication date
WO2002046447A2 (fr) 2002-06-13
WO2002040126A3 (fr) 2006-04-06
AU3922802A (en) 2002-05-27
WO2002028501A1 (fr) 2002-04-11
AU2002239228A8 (en) 2006-11-02
AU1183902A (en) 2002-04-15
AU4146002A (en) 2002-06-18
AU2001296491A1 (en) 2002-04-15
WO2002029006A3 (fr) 2002-08-29
WO2002046447A3 (fr) 2003-12-24
WO2002040126A2 (fr) 2002-05-23

Similar Documents

Publication Publication Date Title
Pusch et al. MALDI-TOF mass spectrometry-based SNP genotyping
JP2004535815A (ja) ニック形成剤を用いた核酸フラグメントの増幅
US6361940B1 (en) Compositions and methods for enhancing hybridization and priming specificity
JP3948746B2 (ja) 質量分析に基づいたｄｎａ診断
US6235476B1 (en) Process for detecting nucleic acids by mass determination
CN106434871B (zh) 用于检测目标核酸的方法与组合物
JP4498657B2 (ja) Ｄｎａサンプル中のシトシン−メチル化とｓｎｐ又は突然変異の同時検出方法
US20040019005A1 (en) Methods for parallel measurement of genetic variations
WO2002029006A2 (fr) Procédé pour le mesurage parallèle des variations génétiques
US20040058349A1 (en) Methods for identifying nucleotides at defined positions in target nucleic acids
WO2002034883A2 (fr) Dosage biologique a un puits destine a la detection a debit eleve de polymorphismes de nucleotides individuels
WO2022051485A2 (fr) Kits de détection d'un ou de plusieurs analytes cibles dans un échantillon et leurs procédés de fabrication et d'utilisation
CA2388561A1 (fr) Procede pour la realisation controlable d'amplifications par pcr complexes
US20040126765A1 (en) Method and compositions for sequencing nucleic acid molecules
WO2004067764A2 (fr) Sequençage d'acide nucleique a l'aide d'agents de coupure de brin
EP0958378A2 (fr) Compositions et procedes pour l'augmentation de la specificite d'hybridation
Peter Single-nucleotide polymorphism genotyping for disease association studies
de Paula Careta et al. Recent patents on high-throughput single nucleotide polymorphism (SNP) genotyping methods
Corona et al. High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry
Gut An overview of genotyping and single nucleotide polymorphisms (SNP)
JP2007174986A (ja) 核酸の塩基配列解析方法
WO2003070977A2 (fr) Procede permettant de detecter des polymorphismes a nucleotide unique
Haff et al. SNP genotyping by MALDI-TOF mass spectrometry
ZA200401157B (en) Amplification of nucleic acid fragments using nicking agents.
EP0952228A2 (fr) Compositions et méthodes pour améliorer la spécificité des hybridations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10398006

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP